{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":191,"total_is_capped":false,"direct_labels_cover":1,"predictions_cover":191,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"fdc8860e50c3","filters":{"venue":"Investigational New Drugs"}},"results":[{"id":"W1964185052","doi":"10.1007/s10637-010-9399-1","title":"A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Population; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Doxorubicin; Chemotherapy; Adenocarcinoma; Surgery; Esophagus; Progressive disease; Oncology; Cancer; Clinical trial","authors":[{"name":"Juan W. Valle","is_ca":false},{"name":"Anne Armstrong","is_ca":false},{"name":"Chris Newman","is_ca":true},{"name":"Valery Yu. Alakhov","is_ca":true},{"name":"Grzegorz Pietrzyński","is_ca":true},{"name":"Julie Brewer","is_ca":false},{"name":"Sue Campbell","is_ca":true},{"name":"Pippa Corrie","is_ca":false},{"name":"Eric K. Rowinsky","is_ca":true},{"name":"Malcolm Ranson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007041558149605497,"gpt":0.2578805014282209,"spread":0.2508389432786154,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001638842,0.001728465,0.002809532,0.000560575,0.0005252198,0.00101131,0.0008173796,0.001853489,0.002538845],"category_scores_gemma":[0.0009597766,0.0007431266,0.001628054,0.0005184307,0.001126302,0.001194969,0.0003505447,0.00406209,0.0006965021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000985028,"about_ca_system_score_gemma":0.001648521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001991031,"about_ca_topic_score_gemma":0.004082134,"domain_scores_codex":[0.9995239,0.0002038902,0.00002058476,0.00008632323,0.00003439259,0.0001308296],"domain_scores_gemma":[0.9994155,0.0001205011,0.00006419541,0.00006261916,0.00004417647,0.0002929547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6579775,0.1498496,0.005368709,0.0008884178,0.001453731,0.0006002564,0.0006845782,0.00434043,0.08744194,0.0005473616,0.003972153,0.08687536],"study_design_scores_gemma":[0.4159316,0.5687101,0.005893917,0.00001814295,0.0004701196,0.0002170659,0.00009425628,0.001230945,0.005242144,0.0001182313,0.002036991,0.00003650075],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947649,0.001186933,0.000474349,0.0004107038,0.0001390159,0.00150657,0.0004893474,0.00004880397,0.0009792768],"genre_scores_gemma":[0.9902954,0.001679687,0.001374964,0.0006763735,0.0001765793,0.001814689,0.001430121,0.00003718285,0.002514932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002809532,"threshold_uncertainty_score":0.008667171,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2088460013","doi":"10.1007/s10637-014-0082-9","title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Rash; Internal medicine; Cancer; Adverse effect; Pharmacodynamics; Breast cancer; Oncology; Tolerability; Phases of clinical research; Colorectal cancer; Clinical trial; Gastroenterology; Pharmacokinetics","authors":[{"name":"Jordi Rodón","is_ca":false},{"name":"Irene Braña","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Maja J. De Jonge","is_ca":false},{"name":"Natasha F Homji","is_ca":false},{"name":"David Mills","is_ca":false},{"name":"Emmanuelle di Tomaso","is_ca":false},{"name":"Céline Sarr","is_ca":false},{"name":"Lucia Trandafir","is_ca":false},{"name":"Cristian Massacesi","is_ca":false},{"name":"Ferry A.L.M. Eskens","is_ca":false},{"name":"Johanna C. Bendell","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009291892874384198,"gpt":0.2711400666733916,"spread":0.2618481737990074,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162879,0.001604494,0.002326386,0.0006332422,0.000450822,0.001101927,0.001056519,0.001144086,0.002907024],"category_scores_gemma":[0.0007330725,0.0006917366,0.001275788,0.0006729442,0.0009802679,0.001089884,0.0004857002,0.005112633,0.000854585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001305185,"about_ca_system_score_gemma":0.001504055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00132167,"about_ca_topic_score_gemma":0.003334597,"domain_scores_codex":[0.9995914,0.0001465165,0.0000158356,0.00007012729,0.00004465229,0.0001314561],"domain_scores_gemma":[0.9995086,0.00005851236,0.00007880715,0.00005478745,0.00002524843,0.000274115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.529977,0.1492973,0.006658042,0.0008987432,0.001850319,0.0002909274,0.0005784447,0.01051455,0.07651227,0.0008630699,0.01331217,0.2092472],"study_design_scores_gemma":[0.5606875,0.4068362,0.01550708,0.00003700909,0.000508476,0.0003848098,0.0001206187,0.004111188,0.006995921,0.0005951358,0.004155405,0.00006081284],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990767,0.002080883,0.0007062385,0.0007555885,0.0001604865,0.001816014,0.001189008,0.0002035529,0.002321225],"genre_scores_gemma":[0.9886308,0.001554365,0.001715258,0.0009352974,0.0000977053,0.002076504,0.002379034,0.00005603439,0.002555085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002907024,"threshold_uncertainty_score":0.009725034,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1902804987","doi":"10.1007/s10637-015-0282-y","title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Adverse effect; Pharmacokinetics; Nausea; Vomiting; Dosing; Tyrosine-kinase inhibitor; Gastroenterology; Pharmacology; Internal medicine; Cancer","authors":[{"name":"Suzanne F. Jones","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Johanna C. Bendell","is_ca":false},{"name":"James M. Cleary","is_ca":false},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Jeffrey R. Infante","is_ca":false},{"name":"Shuchi S. Pandya","is_ca":false},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Kristen J. Pierce","is_ca":false},{"name":"Brett E. Houk","is_ca":false},{"name":"W. Gregory Roberts","is_ca":false},{"name":"S. Martin Shreeve","is_ca":false},{"name":"Geoffrey I. Shapiro","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03517182792736757,"gpt":0.3173592460625452,"spread":0.2821874181351777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001344817,0.001344011,0.002848021,0.0005504364,0.0005105245,0.001130503,0.0007872525,0.001226329,0.00269195],"category_scores_gemma":[0.0007997326,0.0005769072,0.001915694,0.0005814593,0.001062865,0.0009591298,0.0003359764,0.003711285,0.0007105586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008595515,"about_ca_system_score_gemma":0.001567289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001593333,"about_ca_topic_score_gemma":0.003445377,"domain_scores_codex":[0.9996102,0.0001560387,0.00001748623,0.00007507475,0.00003230332,0.0001088936],"domain_scores_gemma":[0.9993451,0.000120043,0.00007025545,0.00005921544,0.00004026885,0.0003650138],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6571305,0.08054183,0.01120493,0.001295315,0.00256148,0.0005784316,0.0006290833,0.005708997,0.07147686,0.0008241986,0.007877774,0.1601707],"study_design_scores_gemma":[0.5370297,0.4408008,0.01073382,0.00003789048,0.0007925271,0.0004121527,0.0001261087,0.001788015,0.00433797,0.0003486604,0.003555315,0.00003695039],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886602,0.003966514,0.000889135,0.0008222197,0.000236542,0.001780708,0.001133495,0.0001123237,0.002398799],"genre_scores_gemma":[0.9864759,0.003768032,0.001653748,0.001130782,0.0002080654,0.00152333,0.002569278,0.0000507283,0.002620172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002848021,"threshold_uncertainty_score":0.009005487,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2063432158","doi":"10.1007/s10637-011-9719-0","title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Sorafenib; Medicine; Internal medicine; Gallbladder; Gastroenterology; Oncology; Carcinoma; Hepatocellular carcinoma; Stage (stratigraphy); Chemotherapy; Gallbladder cancer","authors":[{"name":"Anthony B. El-Khoueiry","is_ca":false},{"name":"Cathryn Rankin","is_ca":false},{"name":"Edgar Ben‐Josef","is_ca":false},{"name":"Heinz‐Josef Lenz","is_ca":false},{"name":"Philip J. Gold","is_ca":false},{"name":"Robert D. Hamilton","is_ca":false},{"name":"Rangaswamy Govindarajan","is_ca":false},{"name":"Cathy Eng","is_ca":false},{"name":"Charles D. Blanke","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04928934074195547,"gpt":0.2755956105989698,"spread":0.2263062698570143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003343249,0.001806035,0.003213156,0.0006994082,0.0005668968,0.00106494,0.0009434691,0.0009602834,0.003085611],"category_scores_gemma":[0.001555958,0.0009009663,0.002567558,0.0008004168,0.001278347,0.001462613,0.0006103276,0.00284073,0.0005935458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00116014,"about_ca_system_score_gemma":0.003063823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001915357,"about_ca_topic_score_gemma":0.006044092,"domain_scores_codex":[0.9991012,0.000579303,0.00005122026,0.00008212253,0.00005227923,0.0001338971],"domain_scores_gemma":[0.9989128,0.0002218646,0.000189667,0.00009387192,0.00007645165,0.0005053153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8113683,0.0409826,0.03477513,0.00165122,0.00606119,0.0002763639,0.0004179105,0.002223189,0.0144802,0.0003614047,0.004466065,0.08293644],"study_design_scores_gemma":[0.6564785,0.2995722,0.03440046,0.00004934148,0.002219566,0.0003278341,0.0002015131,0.000924896,0.001944466,0.00016647,0.00365684,0.00005791236],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949981,0.002284264,0.0002065649,0.0003763201,0.0001059709,0.0007266558,0.000595706,0.00003590621,0.0006704669],"genre_scores_gemma":[0.9885698,0.003253387,0.001399285,0.0007985196,0.000207794,0.001524666,0.002545807,0.00003114834,0.001669595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003343249,"threshold_uncertainty_score":0.017681,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966040155","doi":"10.1007/s10637-007-9044-9","title":"Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Queen's University; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Hamilton Health Sciences; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Nausea; Adverse effect; Internal medicine; Neutropenia; Urology; Vomiting; Clinical trial; Gastroenterology; Oncology; Surgery; Toxicity","authors":[{"name":"Jennifer J. Knox","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":true},{"name":"Eric Winquist","is_ca":true},{"name":"B. Fisher","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05282090444412633,"gpt":0.3459315138132732,"spread":0.2931106093691468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001180169,0.00145762,0.001849557,0.0003829045,0.0005316746,0.0009048988,0.00081299,0.001200892,0.005084876],"category_scores_gemma":[0.001038557,0.0003498142,0.001657178,0.0004705498,0.0006767842,0.0005953123,0.0003037329,0.003062767,0.0008014441],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001693101,"about_ca_system_score_gemma":0.003708234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01097686,"about_ca_topic_score_gemma":0.02711598,"domain_scores_codex":[0.9997041,0.0001459385,0.00001185555,0.00003815051,0.00003442505,0.00006561635],"domain_scores_gemma":[0.9989579,0.0001240732,0.0001575032,0.00004361543,0.00007680852,0.000640025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.82664,0.02330832,0.003893184,0.001334168,0.00213278,0.0003741953,0.0002477176,0.002340475,0.01680133,0.0004911016,0.01664443,0.1057924],"study_design_scores_gemma":[0.8268802,0.1590644,0.007086011,0.00006837435,0.0005118742,0.0003323127,0.00009879418,0.001505876,0.001363168,0.0002554206,0.002789548,0.00004404096],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814641,0.005557549,0.0007059319,0.002133833,0.0005165526,0.002748269,0.002790274,0.0001890465,0.003894456],"genre_scores_gemma":[0.9759642,0.00598539,0.00221146,0.002038277,0.0003247299,0.002197022,0.003500327,0.00006158234,0.007716934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01097686,"threshold_uncertainty_score":0.02182591,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2028577286","doi":"10.1007/s10637-009-9279-8","title":"Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute","keywords":"Viral shedding; Medicine; Viral load; Neutralizing antibody; Virology; Antibody; Virus; Viral replication; Chemotherapy; Oncolytic virus; Immunology; Internal medicine","authors":[{"name":"R. Gollamudi","is_ca":false},{"name":"Mohammad H. Ghalib","is_ca":false},{"name":"Kavita Desai","is_ca":false},{"name":"Imran Chaudhary","is_ca":false},{"name":"Benny Wong","is_ca":false},{"name":"Mark H. Einstein","is_ca":false},{"name":"Matthew Coffey","is_ca":true},{"name":"George M. Gill","is_ca":true},{"name":"K.L. Mettinger","is_ca":true},{"name":"John M. Mariadason","is_ca":false},{"name":"Sridhar Mani","is_ca":false},{"name":"Sanjay Goel","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01033617842663142,"gpt":0.2731821496401648,"spread":0.2628459712135334,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002439635,0.0001958927,0.0004968314,0.00009281645,0.0001449696,0.0003217619,0.0001286768,0.0002762724,0.0007628291],"category_scores_gemma":[0.0007558877,0.00008418328,0.0001643159,0.0001399358,0.0002516665,0.0001882465,0.0001227477,0.00069194,0.0002160328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001623231,"about_ca_system_score_gemma":0.0003014412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002584843,"about_ca_topic_score_gemma":0.000285254,"domain_scores_codex":[0.999889,0.00005131127,0.000003633927,0.0000147664,0.00002099049,0.00002039173],"domain_scores_gemma":[0.9996734,0.000138758,0.0001038386,0.0000362402,0.00001011478,0.00003773265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.03146358,0.001282055,0.05245645,0.0005053075,0.0002095535,0.002773591,0.0003886346,0.001575227,0.3575402,0.002372114,0.004734263,0.544699],"study_design_scores_gemma":[0.008574681,0.1053466,0.3502263,0.0003180786,0.0007274441,0.02721025,0.0004784601,0.01421134,0.4127115,0.003454346,0.07665294,0.00008803695],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750523,0.01040575,0.009510296,0.000726535,0.00006983098,0.00007056504,0.0001880064,0.0003425369,0.003634068],"genre_scores_gemma":[0.9972562,0.0009231787,0.0008448663,0.0001137542,0.00004053703,0.00001498526,0.0001068418,0.00002700995,0.0006726884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007628291,"threshold_uncertainty_score":0.002551913,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2585936581","doi":"10.1007/s10637-017-0438-z","title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":134,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tolerability; Pharmacokinetics; Internal medicine; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Anemia; Gastroenterology; Hypokalemia; Asymptomatic; Hypophosphatemia; Neutropenia; Phases of clinical research; Pharmacology","authors":[{"name":"Siqing Fu","is_ca":false},{"name":"Hal W. Hirte","is_ca":true},{"name":"Stephen Welch","is_ca":true},{"name":"T. Toney Ilenchuk","is_ca":true},{"name":"Tyler Lutes","is_ca":true},{"name":"Christopher Rice","is_ca":true},{"name":"Nigel Fields","is_ca":false},{"name":"Agnes Nemet","is_ca":false},{"name":"Dominique Dugourd","is_ca":true},{"name":"Sarina A. Piha‐Paul","is_ca":false},{"name":"V. Subbiah","is_ca":false},{"name":"L. Liu","is_ca":false},{"name":"Jing Gong","is_ca":false},{"name":"David S. Hong","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03587327682816752,"gpt":0.3115781625913163,"spread":0.2757048857631488,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001298983,0.001077498,0.002214293,0.0003488642,0.0005057195,0.0008733798,0.0006600513,0.0007351195,0.004284276],"category_scores_gemma":[0.0004787146,0.0004964491,0.001102589,0.0003689531,0.0007883207,0.0005588244,0.0003008342,0.002404258,0.0008990502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007972232,"about_ca_system_score_gemma":0.002149331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000768695,"about_ca_topic_score_gemma":0.00252323,"domain_scores_codex":[0.999599,0.0001418495,0.00001865812,0.0000756739,0.00005053609,0.0001142019],"domain_scores_gemma":[0.9995498,0.00005746317,0.00007026663,0.0000427448,0.00004578642,0.0002338688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3929257,0.1229176,0.01071118,0.002570784,0.001516312,0.000570623,0.0005949769,0.007059391,0.2367803,0.0007331553,0.01127534,0.2123446],"study_design_scores_gemma":[0.2677503,0.6894445,0.01044075,0.00005262839,0.0004777393,0.0005032271,0.00007764446,0.002266649,0.02102601,0.0002675045,0.007644977,0.00004809271],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877278,0.002433294,0.001683553,0.0003177141,0.0001277746,0.004101073,0.001653166,0.0002095629,0.001746223],"genre_scores_gemma":[0.9849709,0.001792734,0.003581054,0.0006972958,0.0001370103,0.003264811,0.002191693,0.00006572793,0.003298893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004284276,"threshold_uncertainty_score":0.01433229,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989987919","doi":"10.1007/s10637-006-5938-1","title":"Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Pyrogenesis (Canada); Queen's University; London Health Sciences Centre; Hôpital Notre-Dame; Princess Margaret Cancer Centre; University Health Network; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Medical Research Council; University Health Network","keywords":"Clinical trial; Medicine; Renal cell carcinoma; Cancer; Phases of clinical research; Drug; Oncology; Cancer drugs; Internal medicine; Pharmacology","authors":[{"name":"Eric Winquist","is_ca":true},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Jean-Pierre M. Ayoub","is_ca":true},{"name":"Nancy Wainman","is_ca":true},{"name":"Gregory K. Reid","is_ca":true},{"name":"Laura Pearce","is_ca":true},{"name":"Ajit Shah","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03687109437820722,"gpt":0.3202348674483818,"spread":0.2833637730701745,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332266,0.001816969,0.00302056,0.0006315202,0.000624846,0.001089617,0.001306071,0.001769088,0.003257233],"category_scores_gemma":[0.001094896,0.0006367384,0.001493469,0.0007117324,0.001147619,0.0008314418,0.0003573474,0.003623484,0.0006589172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001782103,"about_ca_system_score_gemma":0.002737392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00682263,"about_ca_topic_score_gemma":0.01849846,"domain_scores_codex":[0.9995682,0.0002001111,0.00001494495,0.00006471273,0.00004086117,0.000111186],"domain_scores_gemma":[0.9991474,0.0001695063,0.0001265848,0.00005809589,0.0000482343,0.0004500703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7898446,0.04182525,0.007683038,0.000679557,0.001407008,0.0003779665,0.00036916,0.004871063,0.0351129,0.0006307121,0.007227986,0.1099708],"study_design_scores_gemma":[0.6726611,0.3076025,0.01068784,0.00003316238,0.0004255932,0.0002170695,0.0001019924,0.001767051,0.003509206,0.0003032532,0.002647931,0.00004337462],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904612,0.002888219,0.0004819217,0.001211901,0.0002482379,0.001403015,0.001175372,0.00009320096,0.002037024],"genre_scores_gemma":[0.9864429,0.003334529,0.001543563,0.001081561,0.0002382748,0.001533627,0.00202149,0.00004564997,0.003758353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00682263,"threshold_uncertainty_score":0.01356578,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2092271538","doi":"10.1007/s10637-015-0221-y","title":"A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":130,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Internal medicine; Tolerability; Toxicity; Gastroenterology; Adverse effect; Surgery; Urology","authors":[{"name":"Quincy S. Chu","is_ca":true},{"name":"Randeep Sangha","is_ca":true},{"name":"Jennifer L. Spratlin","is_ca":true},{"name":"Larissa J. Vos","is_ca":true},{"name":"John R. Mackey","is_ca":true},{"name":"Alexander McEwan","is_ca":true},{"name":"Peter Venner","is_ca":true},{"name":"Evangelos D. Michelakis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0252872114905891,"gpt":0.2869394494576427,"spread":0.2616522379670536,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001358876,0.002171861,0.003221473,0.000890499,0.0007181478,0.00152007,0.001266454,0.001594917,0.003392978],"category_scores_gemma":[0.001137833,0.0009335672,0.001583245,0.0009471731,0.001967385,0.001255895,0.0004564031,0.005427384,0.0008902348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001584851,"about_ca_system_score_gemma":0.003053067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003071463,"about_ca_topic_score_gemma":0.005709439,"domain_scores_codex":[0.9993899,0.0002360313,0.00001919584,0.0001224341,0.00004937599,0.0001830987],"domain_scores_gemma":[0.9987807,0.0002215437,0.0001222756,0.0001340635,0.00006169243,0.0006798148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7359959,0.142522,0.004689347,0.0005155255,0.0009497921,0.0002115424,0.0004505963,0.005313792,0.04029685,0.0005463485,0.004048492,0.06445984],"study_design_scores_gemma":[0.6243231,0.3645577,0.004041685,0.00001760717,0.0002585662,0.000145529,0.00008269523,0.001428054,0.002918812,0.0002874311,0.001903004,0.00003578169],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907816,0.001131002,0.0009214776,0.0007776677,0.0002298029,0.002741254,0.001269799,0.0001016049,0.002045665],"genre_scores_gemma":[0.9847112,0.001813417,0.002685134,0.001475728,0.0002529952,0.003076389,0.002373849,0.00007052166,0.003540696],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003392978,"threshold_uncertainty_score":0.01149899,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","authors":[{"name":"Elisabeth I. Heath","is_ca":false},{"name":"Keith C. Bible","is_ca":false},{"name":"Robert E. Martell","is_ca":true},{"name":"Daniel C. Adelman","is_ca":false},{"name":"Patricia LoRusso","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02381757120153434,"gpt":0.3125895757310258,"spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001635189,0.002271293,0.002580162,0.0007906793,0.000595008,0.0009543988,0.001191539,0.001601028,0.004248644],"category_scores_gemma":[0.001033831,0.0009039931,0.001570868,0.0005615705,0.001557796,0.001036535,0.0003393466,0.004431476,0.00105777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084324,"about_ca_system_score_gemma":0.002696188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002411867,"about_ca_topic_score_gemma":0.007041622,"domain_scores_codex":[0.9995448,0.0002233243,0.00001280033,0.00007223982,0.00004037204,0.0001064363],"domain_scores_gemma":[0.9992385,0.0001587834,0.00008857439,0.00006029831,0.00003858378,0.0004152101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6619341,0.1365551,0.005351201,0.000903803,0.001448444,0.0005040853,0.0005770196,0.005920904,0.07856636,0.0009788224,0.01097191,0.09628828],"study_design_scores_gemma":[0.5571852,0.4229033,0.00623882,0.00002724442,0.0004611403,0.000422429,0.00009726492,0.001906259,0.006479457,0.0003606356,0.003878377,0.00003989723],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879522,0.001995121,0.0009989797,0.0009566107,0.000273222,0.002550493,0.001891814,0.0001507936,0.003230859],"genre_scores_gemma":[0.9752666,0.003319918,0.003351347,0.001611239,0.0003944143,0.003983098,0.005334057,0.0001027092,0.00663673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004248644,"threshold_uncertainty_score":0.01421314,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2035105453","doi":"10.1007/s10637-009-9230-z","title":"A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint-Vincent Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Lung cancer; Overall survival; Oncology; Gastroenterology; Surgery; Chemotherapy","authors":[{"name":"Anne M. Traynor","is_ca":false},{"name":"Ju-Whei Lee","is_ca":false},{"name":"Gerald K. Bayer","is_ca":true},{"name":"John M. Tate","is_ca":false},{"name":"Sachdev Thomas","is_ca":false},{"name":"Miroslaw Mazurczak","is_ca":false},{"name":"David L. Graham","is_ca":false},{"name":"Jill Kolesar","is_ca":false},{"name":"Joan H. Schiller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02281362557493624,"gpt":0.3220910436634508,"spread":0.2992774180885146,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001976415,0.002075808,0.003927079,0.0008069659,0.0006408808,0.001280266,0.001551579,0.002200023,0.00685222],"category_scores_gemma":[0.001080027,0.0009088992,0.002649654,0.0008507752,0.001355812,0.001255986,0.0005387251,0.005398918,0.001762623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001458371,"about_ca_system_score_gemma":0.003128923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003770024,"about_ca_topic_score_gemma":0.0110237,"domain_scores_codex":[0.9994038,0.0002831126,0.00002724939,0.00009997954,0.00003526188,0.0001505461],"domain_scores_gemma":[0.9987105,0.0001997201,0.0001415782,0.00009971248,0.00004891206,0.0007995144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8835042,0.05012492,0.00354538,0.0004245544,0.001535588,0.0002689289,0.0002112224,0.001769803,0.0153667,0.0002545012,0.004587403,0.03840683],"study_design_scores_gemma":[0.7254609,0.2651646,0.005290014,0.00001972352,0.000460225,0.0002010529,0.00006009339,0.0007850743,0.00105637,0.0001481868,0.001321675,0.00003205414],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904268,0.001496303,0.0004486882,0.0006939048,0.0002891293,0.002379885,0.002002206,0.0001224776,0.002140616],"genre_scores_gemma":[0.9802106,0.002432992,0.001813058,0.001587355,0.000300362,0.003443876,0.005132403,0.0000774561,0.00500202],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00685222,"threshold_uncertainty_score":0.02292293,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974638172","doi":"10.1007/s10637-012-9865-z","title":"REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Calgary Laboratory Services; Baker Hughes (Canada); Oncolytics Biotech (Canada); Alberta Cancer Foundation","funders":"Oncolytics Biotech","keywords":"Medicine; Oncolytic virus; Tolerability; Gastroenterology; Toxicity; Internal medicine; Adverse effect; Clinical trial; Cancer; Progressive disease; Surgery; Disease","authors":[{"name":"Don Morris","is_ca":true},{"name":"Xiaolan Feng","is_ca":true},{"name":"Lisa Difrancesco","is_ca":true},{"name":"Kevin Fonseca","is_ca":true},{"name":"Peter Forsyth","is_ca":false},{"name":"Alexander Paterson","is_ca":true},{"name":"Matt Coffey","is_ca":true},{"name":"Brad Thompson","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01760091088536014,"gpt":0.3095962140356946,"spread":0.2919953031503345,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008365326,0.001581955,0.001329092,0.0003707114,0.0003161932,0.00107107,0.0008196629,0.001167175,0.004189499],"category_scores_gemma":[0.0005525703,0.0004017266,0.001298362,0.00027458,0.0008271376,0.0006843481,0.0002806235,0.003866246,0.0009002609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007876746,"about_ca_system_score_gemma":0.001082223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001649019,"about_ca_topic_score_gemma":0.003581172,"domain_scores_codex":[0.9998003,0.00006421577,0.000006415068,0.0000405061,0.00001625079,0.00007235738],"domain_scores_gemma":[0.9996828,0.00007267445,0.00005355188,0.00002846705,0.00001321454,0.0001493333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4962568,0.05562948,0.004357738,0.002113353,0.002186581,0.0004236121,0.0005916462,0.006888844,0.1351195,0.00216533,0.0138978,0.2803694],"study_design_scores_gemma":[0.5869948,0.3741073,0.008500037,0.0001145896,0.0007761572,0.000525094,0.0001624398,0.002714812,0.0156759,0.0006934845,0.009659557,0.00007585171],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841525,0.004621918,0.001267796,0.001295439,0.0003643759,0.001481435,0.001552545,0.0003365125,0.004927461],"genre_scores_gemma":[0.9798791,0.004411222,0.00184867,0.001281601,0.0001517303,0.001543899,0.003294756,0.00009713045,0.007491915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004189499,"threshold_uncertainty_score":0.01401526,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025486703","doi":"10.1007/s10637-005-1157-4","title":"Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Hôpital Notre-Dame; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Nausea; Toxicity; Gastroenterology; Internal medicine; Chemotherapy; Surgery; Progressive disease","authors":[{"name":"D. Scott Ernst","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":true},{"name":"Nancy Wainman","is_ca":true},{"name":"M. L. Davis","is_ca":false},{"name":"Reinhard Lohmann","is_ca":false},{"name":"Tara Baetz","is_ca":false},{"name":"Karl Bélanger","is_ca":true},{"name":"Michael Smylie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01162857412818044,"gpt":0.265100812633515,"spread":0.2534722385053345,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001429649,0.001494095,0.002398034,0.0005421863,0.0005718779,0.0008374354,0.000867401,0.001136199,0.002993616],"category_scores_gemma":[0.0008110857,0.000518405,0.001358589,0.0004438461,0.001184454,0.0009729966,0.0003542262,0.003026756,0.0006944405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008984122,"about_ca_system_score_gemma":0.00146231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001835095,"about_ca_topic_score_gemma":0.004368552,"domain_scores_codex":[0.9996052,0.000180415,0.00001177644,0.00005660219,0.00002436887,0.0001215983],"domain_scores_gemma":[0.9993587,0.0001224164,0.00008161661,0.0000648499,0.00003210382,0.0003404242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6836698,0.1015179,0.01038842,0.0008618374,0.001602343,0.0007046371,0.0005418528,0.005654168,0.06709456,0.0007212395,0.004940076,0.1223032],"study_design_scores_gemma":[0.3035644,0.6748446,0.01226284,0.00003167955,0.0003746998,0.0003479682,0.0001107605,0.001213861,0.004365328,0.0002838856,0.002576606,0.0000235506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936537,0.001723633,0.000488356,0.0005433352,0.00017594,0.001206637,0.0006591778,0.00005008483,0.001499153],"genre_scores_gemma":[0.9909402,0.001916337,0.0008597716,0.0005848852,0.0001812529,0.00173433,0.001207181,0.00002609951,0.002550006],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002993616,"threshold_uncertainty_score":0.01001465,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1997853067","doi":"10.1007/s10637-007-9097-9","title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Melanoma; Neutropenia; Adverse effect; Toxicity; Clinical trial; Internal medicine; Phases of clinical research; Cancer; Pharmacokinetics; Chemotherapy; Surgery; Oncology; Gastroenterology; Cancer research","authors":[{"name":"Christopher W. Lee","is_ca":true},{"name":"Karl Bélanger","is_ca":true},{"name":"Sanjay C. Rao","is_ca":true},{"name":"Teresa M. Petrella","is_ca":true},{"name":"Richard Tozer","is_ca":true},{"name":"Lori Wood","is_ca":true},{"name":"Kerry J. Savage","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true},{"name":"Timothy W. Synold","is_ca":false},{"name":"Nancy Wainman","is_ca":true},{"name":"Lesley Seymour","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08669226906530368,"gpt":0.3826761406183515,"spread":0.2959838715530478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00174959,0.002220548,0.002702572,0.0004334063,0.0006514749,0.001235781,0.001092705,0.001765817,0.005170634],"category_scores_gemma":[0.0009803823,0.000632295,0.001929108,0.0005635969,0.001114266,0.0008439352,0.0003532755,0.004367909,0.001359885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00189869,"about_ca_system_score_gemma":0.003026289,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008539056,"about_ca_topic_score_gemma":0.02707331,"domain_scores_codex":[0.9995149,0.000223639,0.00001381872,0.00006749987,0.00004282479,0.0001373809],"domain_scores_gemma":[0.9991818,0.00008904144,0.0001162206,0.00005223107,0.00005251141,0.0005081634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8258075,0.02431648,0.005841695,0.001227849,0.002430946,0.0003746024,0.000266931,0.002809132,0.0182026,0.0005659271,0.01643769,0.1017186],"study_design_scores_gemma":[0.8363798,0.1476073,0.00854144,0.0000514484,0.0006358831,0.0002597553,0.00006775818,0.0009842357,0.001013774,0.0002543578,0.004167975,0.00003624082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746298,0.007309091,0.0006814944,0.002418208,0.0005669715,0.003438944,0.003807678,0.0001820801,0.006965789],"genre_scores_gemma":[0.9724955,0.005933739,0.001721763,0.002633131,0.0004425647,0.00262513,0.005777352,0.00006185903,0.008309139],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9914609,"threshold_uncertainty_score":0.01729751,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W264127248","doi":"10.1023/a:1022976528441","title":"Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pyrogenesis (Canada); BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Pharmacokinetics; Pharmacology; Toxicity; Medicine; DNMT1; Hemoglobin; Chemistry; Methyltransferase; Internal medicine; DNA; Biochemistry","authors":[{"name":"Alison Davis","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Carolyn D. Britten","is_ca":true},{"name":"Nisha Mistry","is_ca":true},{"name":"Henry J. Klamut","is_ca":true},{"name":"Susan D’Aloisio","is_ca":true},{"name":"Martha MacLean","is_ca":true},{"name":"Nancy Wainman","is_ca":false},{"name":"D. Ayers","is_ca":true},{"name":"P. Firby","is_ca":true},{"name":"Jeffrey M. Besterman","is_ca":true},{"name":"Gregory K. Reid","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01797658233807913,"gpt":0.306791163502084,"spread":0.2888145811640048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006521667,0.001772536,0.002158019,0.0006839937,0.0005746607,0.0009306325,0.00138742,0.001842919,0.002175807],"category_scores_gemma":[0.0005875537,0.0008488044,0.0009785271,0.0005151051,0.001248458,0.0007252134,0.0002229997,0.002985452,0.0006598964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000942828,"about_ca_system_score_gemma":0.002302634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001699357,"about_ca_topic_score_gemma":0.003296822,"domain_scores_codex":[0.9996093,0.0001309121,0.00001314392,0.0000769227,0.00004001578,0.0001297543],"domain_scores_gemma":[0.9995171,0.00008435821,0.0001047923,0.00006011534,0.00003527624,0.0001985035],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6192992,0.1118987,0.003028776,0.0004443997,0.0007322829,0.0003543013,0.0002758073,0.004467477,0.1720553,0.001276644,0.00469985,0.08146723],"study_design_scores_gemma":[0.2683624,0.6984095,0.003582454,0.00002612131,0.0003146454,0.0002582054,0.00007770913,0.001239314,0.02288548,0.0003650308,0.004440029,0.00003914625],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910255,0.001387782,0.001156111,0.0004454753,0.0002183334,0.002422871,0.0009352496,0.000135303,0.002273311],"genre_scores_gemma":[0.9833808,0.001802259,0.002427538,0.0006971334,0.0002542064,0.004104647,0.001498939,0.00005775337,0.005776748],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002175807,"threshold_uncertainty_score":0.0072788,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000123112","doi":"10.1023/b:drug.0000026258.02846.1c","title":"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"National Cancer Institute; McGill University","keywords":"Nausea; Medicine; Gastroenterology; Internal medicine; Vomiting; Diarrhea; Melanoma; Progressive disease; Anorexia; Toxicity; Regimen; Phases of clinical research; Surgery; Chemotherapy; Cancer research","authors":[{"name":"Susan Burdette-Radoux","is_ca":true},{"name":"Richard Tozer","is_ca":true},{"name":"Reinhard Lohmann","is_ca":true},{"name":"Ian Quirt","is_ca":true},{"name":"D. Scott Ernst","is_ca":false},{"name":"Wendy Walsh","is_ca":false},{"name":"Nancy Wainman","is_ca":false},{"name":"A. Dimitrios Colevas","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02107754542709329,"gpt":0.2726131858557945,"spread":0.2515356404287012,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009792295,0.001290132,0.001831726,0.0004425451,0.0004952002,0.0007672113,0.0008108979,0.00112825,0.002803592],"category_scores_gemma":[0.0007221702,0.0004698168,0.0009505878,0.0003532533,0.0009513634,0.0007432466,0.0002366713,0.002763746,0.0005181325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008702683,"about_ca_system_score_gemma":0.0009450795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002040631,"about_ca_topic_score_gemma":0.004979413,"domain_scores_codex":[0.9997649,0.00009641721,0.000007196417,0.00003215358,0.00001945145,0.00007996461],"domain_scores_gemma":[0.9995629,0.00008820092,0.00005260638,0.0000349211,0.0000204865,0.0002409101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7272049,0.05093186,0.004622452,0.001011858,0.001173615,0.0005914388,0.0004397559,0.004543983,0.07544234,0.0009130421,0.00648013,0.1266446],"study_design_scores_gemma":[0.4745232,0.4989129,0.01168799,0.00006081513,0.0004068326,0.0004321541,0.0001515262,0.002007929,0.007267707,0.0004853298,0.004023065,0.00004045975],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913124,0.003414681,0.0004739635,0.0006838046,0.0002307571,0.000910648,0.0006205802,0.00007181702,0.002281263],"genre_scores_gemma":[0.9884322,0.003143045,0.0008225768,0.0005568094,0.0002018464,0.001059503,0.001235714,0.0000271165,0.004521092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002803592,"threshold_uncertainty_score":0.00937897,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2083983329","doi":"10.1007/s10637-006-6406-7","title":"A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Juravinski Cancer Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Vomiting; Sarcoma; Soft tissue sarcoma; Internal medicine; Adverse effect; Toxicity; Progressive disease; Surgery; Population; Dosing; Gastroenterology; Phases of clinical research; Chemotherapy; Soft tissue; Pathology","authors":[{"name":"Meg Knowling","is_ca":true},{"name":"Martin E. Blackstein","is_ca":true},{"name":"Richard Tozer","is_ca":true},{"name":"V. Bramwell","is_ca":false},{"name":"Janet Dancey","is_ca":false},{"name":"Naomi Dore","is_ca":false},{"name":"S. Matthews","is_ca":false},{"name":"E. Eisenhauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04329356748062302,"gpt":0.3666796670381587,"spread":0.3233860995575357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001214944,0.0018861,0.002140336,0.0004315893,0.0004675889,0.0009194906,0.00089297,0.00126468,0.003774829],"category_scores_gemma":[0.0007510401,0.0005142986,0.001246536,0.000525538,0.00114022,0.0006962748,0.0003399265,0.002515405,0.001004652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001305231,"about_ca_system_score_gemma":0.002433741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004451155,"about_ca_topic_score_gemma":0.01375438,"domain_scores_codex":[0.9996998,0.00013949,0.000008549999,0.00004430479,0.00002213011,0.00008567593],"domain_scores_gemma":[0.9993966,0.00007283942,0.000094544,0.00004075484,0.00003074518,0.0003645535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8385738,0.0280493,0.005982309,0.0007494303,0.00129167,0.0004844561,0.0002508329,0.003879474,0.02905443,0.0006115599,0.008988122,0.08208457],"study_design_scores_gemma":[0.7794712,0.2048387,0.009198369,0.00003366547,0.000374744,0.0003256727,0.00006344916,0.0009440257,0.001519991,0.0002726016,0.002926518,0.00003111265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899739,0.002574194,0.0004360701,0.001094205,0.0001830196,0.001665208,0.001628784,0.00009376816,0.002350891],"genre_scores_gemma":[0.9843886,0.003075622,0.00133515,0.001245221,0.0001749498,0.00217676,0.00305083,0.00003355271,0.004519347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004451155,"threshold_uncertainty_score":0.01262802,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1991823030","doi":"10.1007/s10637-007-9066-3","title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Pancreatic carcinoma; Medicine; Internal medicine; Phases of clinical research; Oncology; Deoxycytidine; Chemotherapy; Pancreatic cancer; Cancer","authors":[{"name":"Mary J. MacKenzie","is_ca":false},{"name":"David L. Saltman","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Jennifer A. Low","is_ca":false},{"name":"C. Johnson","is_ca":true},{"name":"Gregory R. Pond","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02548080054953892,"gpt":0.338689633946706,"spread":0.313208833397167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001890639,0.001634908,0.001768524,0.0005353982,0.0004560846,0.0009299612,0.001199874,0.001758446,0.00411834],"category_scores_gemma":[0.001140954,0.000696165,0.001441807,0.0005692803,0.001081636,0.0008720314,0.0004242662,0.003955918,0.0007965231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000875675,"about_ca_system_score_gemma":0.001422163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001739647,"about_ca_topic_score_gemma":0.003355467,"domain_scores_codex":[0.9995353,0.0002690675,0.00001576798,0.00005792671,0.00003340276,0.00008864346],"domain_scores_gemma":[0.9988808,0.0002499654,0.0001635602,0.00008916627,0.00004587204,0.000570611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8256336,0.05340433,0.004101967,0.0006361656,0.001279507,0.0004740715,0.0003251249,0.002525919,0.02864628,0.0004990714,0.006496603,0.07597728],"study_design_scores_gemma":[0.791958,0.1969575,0.004809177,0.00002246413,0.0002986199,0.0002877135,0.00006233191,0.0007728906,0.002323465,0.0001836216,0.002300817,0.00002338807],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912049,0.002693296,0.0004509396,0.0008699403,0.0002196095,0.001444455,0.0007537701,0.00007456341,0.002288427],"genre_scores_gemma":[0.9838145,0.003528122,0.001614219,0.001649086,0.000295911,0.001923684,0.002702927,0.00005104682,0.004420379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00411834,"threshold_uncertainty_score":0.01377726,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2074077730","doi":"10.1007/s10637-008-9190-8","title":"Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Colorectal cancer; Internal medicine; Chemotherapy; Oncology; Regimen; Performance status; Mucositis; Induction chemotherapy; Cancer; Surgery; Histone deacetylase; Biology; Histone","authors":[{"name":"Robert P. Whitehead","is_ca":false},{"name":"Cathryn Rankin","is_ca":false},{"name":"Paulo M. Hoff","is_ca":false},{"name":"Philip J. Gold","is_ca":false},{"name":"Kevin G. Billingsley","is_ca":false},{"name":"Robert Chapman","is_ca":false},{"name":"Lucas Wong","is_ca":false},{"name":"John H. Ward","is_ca":false},{"name":"James L. Abbruzzese","is_ca":false},{"name":"Charles D. Blanke","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0150066062739379,"gpt":0.3032035776085973,"spread":0.2881969713346594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001368981,0.00208435,0.002875146,0.0004869725,0.0004713646,0.0009210409,0.001061638,0.001371124,0.004112331],"category_scores_gemma":[0.0007252908,0.0006339309,0.001894449,0.0005856714,0.001222596,0.0008032229,0.000439674,0.003659264,0.001224868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001187387,"about_ca_system_score_gemma":0.002447294,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003682912,"about_ca_topic_score_gemma":0.01156045,"domain_scores_codex":[0.9996308,0.0001786641,0.00001473609,0.00005982265,0.0000247109,0.0000911963],"domain_scores_gemma":[0.9991272,0.000096891,0.0001274289,0.00006103086,0.00003367264,0.0005537823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8551337,0.03381192,0.008348008,0.0004775291,0.001727502,0.0003192752,0.0002335798,0.002781323,0.02594173,0.000235335,0.005691161,0.06529902],"study_design_scores_gemma":[0.6952971,0.2839941,0.01478259,0.00002377072,0.0005288332,0.0002972617,0.00007084549,0.001088192,0.001800305,0.0001643192,0.001924831,0.00002790961],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932995,0.001575328,0.0003262212,0.0007166256,0.0001838628,0.00103002,0.001445881,0.0001045371,0.001317953],"genre_scores_gemma":[0.9830697,0.002777353,0.001558078,0.00122796,0.0002900943,0.001614063,0.005082017,0.00004996304,0.004330957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004112331,"threshold_uncertainty_score":0.01375711,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2014952173","doi":"10.1007/s10637-007-9098-8","title":"Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":81,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Neutropenia; Leukopenia; Chemotherapy; Internal medicine; Gastroenterology; Head and neck squamous-cell carcinoma; Adverse effect; Phases of clinical research; Oncology; Surgery; Head and neck cancer; Radiation therapy","authors":[{"name":"Patricia A. Tang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Stephen Chia","is_ca":true},{"name":"James K. Schwarz","is_ca":true},{"name":"Gregory R. Pond","is_ca":true},{"name":"Caitlin Johnson","is_ca":true},{"name":"A. Dimitrios Colevas","is_ca":false},{"name":"Timothy W. Synold","is_ca":false},{"name":"Lakshmi Vasist","is_ca":false},{"name":"Eric Winquist","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02060612412244646,"gpt":0.2880066215949376,"spread":0.2674004974724912,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001165069,0.001469512,0.002501281,0.0005345359,0.0005475437,0.0009745084,0.001060295,0.001208257,0.003548282],"category_scores_gemma":[0.0005826051,0.0005161736,0.001327274,0.0005333325,0.0009641299,0.0007450812,0.0003053958,0.002942344,0.0007572424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001314442,"about_ca_system_score_gemma":0.001932258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003620065,"about_ca_topic_score_gemma":0.008560816,"domain_scores_codex":[0.9996798,0.0001272451,0.00001108644,0.00004461443,0.00002763843,0.0001095881],"domain_scores_gemma":[0.999579,0.00006464891,0.00005943005,0.00004297307,0.00003645581,0.0002174309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5885314,0.07078668,0.01306644,0.002015416,0.002583085,0.0008935545,0.0009045352,0.009076698,0.0936441,0.001160649,0.01297604,0.2043615],"study_design_scores_gemma":[0.3390276,0.6165889,0.01655149,0.00008975224,0.0009377369,0.0008969906,0.0003542178,0.003079616,0.01435791,0.0004596435,0.00759211,0.00006407144],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990311,0.002976267,0.0004435532,0.0004279147,0.0001758259,0.001618614,0.001213306,0.00007433188,0.002759199],"genre_scores_gemma":[0.9847078,0.003603151,0.0009375974,0.0005778497,0.000154661,0.001908413,0.003001497,0.00004142128,0.00506741],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003620065,"threshold_uncertainty_score":0.01187021,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2492626689","doi":"10.1007/s10637-016-0377-0","title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Dosing; Tolerability; Trametinib; Medicine; Adverse effect; Rash; MEK inhibitor; Pharmacokinetics; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; MAPK/ERK pathway; Biology","authors":[{"name":"Juneko E. Grilley‐Olson","is_ca":false},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Angelica Fasolo","is_ca":false},{"name":"Mark Cornfeld","is_ca":false},{"name":"Leanne Cartee","is_ca":false},{"name":"A.R. Abdul Razak","is_ca":true},{"name":"Lee-Anne Stayner","is_ca":true},{"name":"Yuhui Wu","is_ca":false},{"name":"Ryan Greenwood","is_ca":false},{"name":"R. Singh","is_ca":false},{"name":"Chul‐min Lee","is_ca":false},{"name":"Johanna C. Bendell","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Gianluca Del Conte","is_ca":false},{"name":"Cristiana Sessa","is_ca":false},{"name":"Jeffrey R. Infante","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007907842871237351,"gpt":0.248194676809058,"spread":0.2402868339378207,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001357325,0.001606287,0.002601137,0.0007665353,0.0005286481,0.001295579,0.0009476141,0.001320461,0.003977425],"category_scores_gemma":[0.000976295,0.000873111,0.00204882,0.0007324419,0.001095778,0.001371851,0.0004471965,0.00499915,0.001084932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001370496,"about_ca_system_score_gemma":0.001810671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001680522,"about_ca_topic_score_gemma":0.005255118,"domain_scores_codex":[0.9995942,0.0001439996,0.00002160986,0.00008498311,0.00003705884,0.0001182939],"domain_scores_gemma":[0.9993716,0.00008363322,0.0000885579,0.00006931236,0.00003788027,0.0003490289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7061063,0.0927025,0.006662945,0.0008648147,0.002071219,0.0003145408,0.0004415934,0.006387265,0.03393732,0.000530385,0.005627205,0.144354],"study_design_scores_gemma":[0.6028264,0.3774505,0.01124383,0.00003740057,0.0005957182,0.0003036552,0.0001015789,0.001825808,0.002535819,0.0003421995,0.002689239,0.0000478612],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918542,0.001753501,0.0004520573,0.0007018751,0.0002157265,0.001838694,0.0009872726,0.0001215729,0.002075067],"genre_scores_gemma":[0.98964,0.001894517,0.001457589,0.000772963,0.0001414385,0.001544899,0.001855145,0.00004158764,0.002651932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003977425,"threshold_uncertainty_score":0.01330578,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1976371429","doi":"10.1007/s10637-013-9965-4","title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Gemcitabine; Pharmacokinetics; Medicine; Tolerability; Neutropenia; Pharmacology; Internal medicine; Rash; Gastroenterology; Toxicity; Adverse effect; Chemotherapy","authors":[{"name":"Suzanne Richter","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Eric Xueyu Chen","is_ca":true},{"name":"Blaise Clarke","is_ca":true},{"name":"Ben Tran","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Anastasios Stathis","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Michael Reedijk","is_ca":true},{"name":"Zhuo Chen","is_ca":true},{"name":"Brenda Cohen","is_ca":true},{"name":"Wenjiang Zhang","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"S. Percy Ivy","is_ca":false},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Elaine McWhirter","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00475852084442618,"gpt":0.2224707915848854,"spread":0.2177122707404593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008606234,0.001317943,0.002126342,0.0004680087,0.0003081905,0.0009182614,0.0009689614,0.000873915,0.002788003],"category_scores_gemma":[0.0005499015,0.0005007182,0.0009411518,0.0005217731,0.0007571529,0.000734833,0.0003841965,0.002770092,0.0008479878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001011507,"about_ca_system_score_gemma":0.001689317,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008630764,"about_ca_topic_score_gemma":0.002615952,"domain_scores_codex":[0.9996371,0.0001463668,0.00002321048,0.00007131176,0.00004923401,0.00007268922],"domain_scores_gemma":[0.999572,0.00005135922,0.0001091638,0.00003783006,0.0000183535,0.0002113528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5264036,0.1058589,0.0113536,0.001297953,0.00198719,0.0006768389,0.000380004,0.005746265,0.1282992,0.0004165599,0.00495975,0.2126202],"study_design_scores_gemma":[0.3555793,0.6147395,0.01382154,0.00004346809,0.0005752864,0.0006374244,0.00007510919,0.001722888,0.00913553,0.0001373441,0.003497354,0.00003532994],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939439,0.001801756,0.0004618189,0.0002466668,0.00005240773,0.001597967,0.0005671084,0.00007714038,0.001251199],"genre_scores_gemma":[0.9903632,0.00189777,0.002007427,0.0005069007,0.00009772691,0.001638423,0.001753061,0.00002654109,0.001708978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002788003,"threshold_uncertainty_score":0.009326816,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1991064094","doi":"10.1007/s10637-010-9408-4","title":"A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Sorafenib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Clinical endpoint; Internal medicine; Oncology; Surgery; Phases of clinical research; Clinical trial; Chemotherapy; Hepatocellular carcinoma","authors":[{"name":"Srikala S. Sridhar","is_ca":false},{"name":"Eric Winquist","is_ca":false},{"name":"Andrea Eisen","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Elaine McWhirter","is_ca":true},{"name":"Ian F. Tannock","is_ca":true},{"name":"Som D. Mukherjee","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Chantale Blattler","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04450204486330388,"gpt":0.3536828405025805,"spread":0.3091807956392766,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002833671,0.0015708,0.002693987,0.0004930369,0.0006540555,0.001091217,0.0008866705,0.001396256,0.004330026],"category_scores_gemma":[0.002107863,0.0005098826,0.001644234,0.0004061811,0.001010514,0.0009995264,0.0006715638,0.004088081,0.0007262782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032709,"about_ca_system_score_gemma":0.002196291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001302149,"about_ca_topic_score_gemma":0.002701639,"domain_scores_codex":[0.9992229,0.0004763158,0.00001960465,0.0001026888,0.00005684491,0.0001216158],"domain_scores_gemma":[0.9982173,0.0003438111,0.0002033723,0.0001402983,0.00008441258,0.001010803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7696248,0.03879444,0.007842019,0.0008819663,0.002016834,0.0003782269,0.0003395806,0.003354161,0.01911774,0.0006150457,0.01302,0.1440151],"study_design_scores_gemma":[0.8505197,0.1353879,0.008335232,0.00002360222,0.0003785406,0.0002796304,0.00006251864,0.001154179,0.001260321,0.0003448517,0.002224043,0.00002956097],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902872,0.002186493,0.0004868018,0.0016379,0.0002190604,0.001966073,0.001534727,0.0000851699,0.001596472],"genre_scores_gemma":[0.982081,0.00208074,0.003025442,0.001984754,0.0003998995,0.002794288,0.004107604,0.0000601386,0.003466092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004330026,"threshold_uncertainty_score":0.01498604,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","authors":[{"name":"Shivaani Kummar","is_ca":false},{"name":"James L. Wade","is_ca":false},{"name":"Amit M. Oza","is_ca":true},{"name":"Daniel M. Sullivan","is_ca":false},{"name":"Alice P. Chen","is_ca":false},{"name":"David R. Gandara","is_ca":false},{"name":"Jiuping Ji","is_ca":false},{"name":"Robert J. Kinders","is_ca":false},{"name":"Lihua Wang","is_ca":false},{"name":"Deborah Allen","is_ca":false},{"name":"Geraldine O’Sullivan Coyne","is_ca":false},{"name":"Seth M. Steinberg","is_ca":false},{"name":"James H. Doroshow","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01259685493353731,"gpt":0.2914200369288869,"spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001453006,0.001624491,0.003133881,0.0003629838,0.0004370793,0.001467146,0.001025605,0.001531784,0.008649279],"category_scores_gemma":[0.001831486,0.0008838064,0.001647105,0.0004771647,0.001420369,0.001160739,0.0005430019,0.004484181,0.001348142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139881,"about_ca_system_score_gemma":0.00145967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001489105,"about_ca_topic_score_gemma":0.003701757,"domain_scores_codex":[0.9993941,0.0003226557,0.00002793618,0.00012266,0.00003047046,0.000102267],"domain_scores_gemma":[0.9989441,0.0003094677,0.0001857232,0.0001104339,0.00004870674,0.0004015133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9793842,0.005052014,0.0005259374,0.0002632641,0.0007461975,0.00003455316,0.00003798645,0.0004922466,0.001607927,0.0001432824,0.0008846825,0.0108277],"study_design_scores_gemma":[0.967272,0.03040057,0.0007364611,0.00001272813,0.0002570269,0.00002700282,0.00001958701,0.0003478615,0.0001807484,0.0001628832,0.0005745239,0.000008655544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804084,0.00454415,0.001148102,0.001520571,0.001194341,0.004668663,0.001952357,0.0001784604,0.004384933],"genre_scores_gemma":[0.9793968,0.002997877,0.001827256,0.002067247,0.0006384556,0.004459908,0.002229126,0.00005619392,0.006327215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008649279,"threshold_uncertainty_score":0.02893478,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1539780911","doi":"10.1007/s10637-006-9022-7","title":"A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Adverse effect; Rash; Internal medicine; Multiple myeloma; Nausea; Vomiting; Clinical endpoint; Anemia; Gastroenterology; Phases of clinical research; Diarrhea; Pharmacokinetics; Pharmacology; Clinical trial; Oncology","authors":[{"name":"Michael J. Kovacs","is_ca":true},{"name":"Donna Reece","is_ca":false},{"name":"Deborah Marcellus","is_ca":false},{"name":"Ralph M. Meyer","is_ca":false},{"name":"Sarah Mathews","is_ca":false},{"name":"Rui-Ping Dong","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01286201718875107,"gpt":0.2673898610740773,"spread":0.2545278438853262,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001110633,0.001199012,0.002201369,0.0005643938,0.000456135,0.000815575,0.00110376,0.001172077,0.002965096],"category_scores_gemma":[0.0007172703,0.0005972835,0.001300584,0.000508171,0.0007444109,0.0006472462,0.0003139745,0.003328013,0.0007690914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001056945,"about_ca_system_score_gemma":0.001635376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003755022,"about_ca_topic_score_gemma":0.008336283,"domain_scores_codex":[0.9996619,0.0001407951,0.00001502253,0.00005148429,0.00003737334,0.00009339597],"domain_scores_gemma":[0.9995019,0.00007577126,0.00005542307,0.00003193497,0.00002908097,0.0003059003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7300462,0.05789541,0.0116138,0.0007567616,0.002439,0.0005770721,0.0003742915,0.003030255,0.04306946,0.0004777109,0.009887362,0.1398327],"study_design_scores_gemma":[0.6224509,0.3470026,0.02019998,0.00003144983,0.0007238527,0.000424406,0.00008305976,0.00146731,0.002744672,0.0001704176,0.00465939,0.00004203479],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884289,0.003885464,0.0005312228,0.0008243825,0.0002420899,0.001978045,0.001420708,0.0001281593,0.002560884],"genre_scores_gemma":[0.9851769,0.002990302,0.001674586,0.001276155,0.0002494399,0.001077876,0.003840711,0.00003086821,0.003683112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003755022,"threshold_uncertainty_score":0.009919226,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1977529605","doi":"10.1007/s10637-014-0066-9","title":"Phase II trial of vorinostat in advanced melanoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Vorinostat; Clinical endpoint; Medicine; Melanoma; Adverse effect; Nausea; Internal medicine; Oncology; Progressive disease; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy; Randomized controlled trial; Cancer research; Histone deacetylase; Histone; Biology","authors":[{"name":"Naomi B. Haas","is_ca":false},{"name":"Ian Quirt","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Elaine McWhirter","is_ca":true},{"name":"R. Polintan","is_ca":true},{"name":"Samuel Litwin","is_ca":false},{"name":"Peter D. Adams","is_ca":false},{"name":"Tony McBryan","is_ca":false},{"name":"L. Wang","is_ca":true},{"name":"Lainie P. Martin","is_ca":false},{"name":"Margaret vonMehren","is_ca":false},{"name":"R. Katherine Alpaugh","is_ca":false},{"name":"James Zweibel","is_ca":false},{"name":"Amit M. Oza","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01300294792304773,"gpt":0.2994760520324806,"spread":0.2864731041094329,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009829482,0.001479951,0.002021085,0.0005664434,0.0005356312,0.001002773,0.0006998265,0.001152768,0.005049392],"category_scores_gemma":[0.0005601037,0.0004722961,0.00120558,0.0004020216,0.0009770828,0.0008160818,0.0003144293,0.002833804,0.0009922151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009938901,"about_ca_system_score_gemma":0.001196299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001997523,"about_ca_topic_score_gemma":0.00441551,"domain_scores_codex":[0.9997626,0.00009785001,0.000007948768,0.00003482451,0.00001796728,0.00007879711],"domain_scores_gemma":[0.9995667,0.00007333238,0.00004428711,0.00003409323,0.00001755314,0.0002639398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7203366,0.04620254,0.004454214,0.001211002,0.001155669,0.0006971311,0.0004192819,0.005264089,0.06652183,0.0009562297,0.01034594,0.1424356],"study_design_scores_gemma":[0.5724859,0.4045887,0.008427967,0.00006373781,0.000331461,0.0003601363,0.0001432265,0.002077088,0.005774871,0.0005516208,0.005159352,0.00003581985],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848664,0.004388374,0.0006212661,0.001509287,0.0005606568,0.001875806,0.001690155,0.0001419261,0.004346087],"genre_scores_gemma":[0.9801362,0.00385748,0.001092513,0.001186659,0.0003241648,0.001769147,0.003402849,0.00004898575,0.008182024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005049392,"threshold_uncertainty_score":0.01689184,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025697283","doi":"10.1007/s10637-015-0216-8","title":"The oncolytic virus, pelareorep, as a novel anticancer agent: a review","year":2015,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Oncolytic virus; Virus; Virology; Medicine","authors":[{"name":"Romit Chakrabarty","is_ca":true},{"name":"Hue Tran","is_ca":true},{"name":"Giovanni Selvaggi","is_ca":true},{"name":"Allison Hagerman","is_ca":true},{"name":"Brad Thompson","is_ca":true},{"name":"Matt Coffey","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0784854877160039,"gpt":0.3969353303191214,"spread":0.3184498426031175,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004157042,0.000738802,0.001145898,0.001956744,0.0002638396,0.0008787622,0.0007843812,0.0008739554,0.002196173],"category_scores_gemma":[0.0004778582,0.0003040006,0.0003538347,0.001901991,0.0003797518,0.001311226,0.000542853,0.001508052,0.001151636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005697013,"about_ca_system_score_gemma":0.001000144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009125203,"about_ca_topic_score_gemma":0.001850497,"domain_scores_codex":[0.9998946,0.00001182594,0.00001552946,0.00002246314,0.0000421889,0.00001337668],"domain_scores_gemma":[0.9998127,0.00008290887,0.00003422601,0.00000503377,0.00004290255,0.00002224993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001242815,0.0001013438,0.0001849819,0.0189472,0.00008954681,0.0002658671,0.00006309545,0.0004349488,0.007846693,0.003925741,0.02667475,0.9413415],"study_design_scores_gemma":[0.00002110909,0.000128849,0.0003907638,0.001462594,0.0001419007,0.001050074,0.00004154797,0.0001230569,0.002052142,0.001143118,0.9934235,0.00002133824],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001499578,0.9988488,0.0001678657,0.000133809,0.0001261578,0.000004242728,0.00001781495,0.000006323806,0.0005449886],"genre_scores_gemma":[0.0006985605,0.9984708,0.0002155654,0.0001193914,0.00008141714,0.000004871913,0.00002668571,0.000001108687,0.0003815599],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002196173,"threshold_uncertainty_score":0.007346869,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2081181781","doi":"10.1007/s10637-007-9103-2","title":"A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; Cancer Care Ontario; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Leukocytopenia; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Phases of clinical research; Cancer; Liver function; Pharmacokinetics; Neutropenia; Toxicity; Oncology; Surgery","authors":[{"name":"Jennifer J. Knox","is_ca":true},{"name":"Sharlene Gill","is_ca":true},{"name":"Timothy W. Synold","is_ca":false},{"name":"James Biagi","is_ca":true},{"name":"Pierre Major","is_ca":true},{"name":"Ron Feld","is_ca":true},{"name":"C. Cripps","is_ca":true},{"name":"Nancy Wainman","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true},{"name":"Lesley Seymour","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06080585527464875,"gpt":0.3347445557224106,"spread":0.2739387004477618,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001262617,0.002029021,0.002966561,0.0006593852,0.000577265,0.0009939304,0.00091492,0.001608033,0.003154816],"category_scores_gemma":[0.001203059,0.0008347323,0.001407676,0.0007868287,0.001164445,0.001075626,0.0003276724,0.004375518,0.001146822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001380149,"about_ca_system_score_gemma":0.00222876,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005782236,"about_ca_topic_score_gemma":0.009931062,"domain_scores_codex":[0.9996351,0.0001685087,0.00001287973,0.00005468142,0.00004046377,0.00008833466],"domain_scores_gemma":[0.9991832,0.0001196331,0.0001148199,0.0000686718,0.00004674813,0.000466882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7036815,0.06838562,0.01238903,0.0008093162,0.00185561,0.0006014858,0.0004324637,0.005207717,0.06376314,0.0004856749,0.009530139,0.1328582],"study_design_scores_gemma":[0.5946732,0.3752063,0.01948383,0.00002986109,0.0005391782,0.0004830904,0.0001041779,0.001808698,0.0039824,0.000268003,0.003349978,0.00007114794],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901816,0.002845211,0.0006372107,0.000932641,0.0001622174,0.001402382,0.001799978,0.0001199487,0.001918834],"genre_scores_gemma":[0.9853909,0.00344615,0.001905595,0.001124376,0.0002199412,0.001634717,0.002965148,0.00007633486,0.003236838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9942178,"threshold_uncertainty_score":0.0114972,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2093988174","doi":"10.1007/s10637-012-9886-7","title":"The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Abbott Laboratories","keywords":"PARP inhibitor; Irinotecan; Cancer research; Veliparib; Poly ADP ribose polymerase; Olaparib; Oxaliplatin; DNA damage; PARP1; Cancer; Synthetic lethality; DNA repair; Base excision repair; Colorectal cancer; Biology; Medicine; Polymerase; Internal medicine; DNA; Biochemistry","authors":[{"name":"David Davidson","is_ca":true},{"name":"Yunzhe Wang","is_ca":true},{"name":"Raquel Aloyz","is_ca":true},{"name":"Lawrence Panasci","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03616634036575846,"gpt":0.3192929074536835,"spread":0.2831265670879251,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002610088,0.0006067051,0.0008596088,0.0008628988,0.0003239188,0.0004633026,0.0003431115,0.0003596437,0.003237163],"category_scores_gemma":[0.0002598166,0.0003156075,0.0005106649,0.0008052929,0.0002484216,0.0004547687,0.0003411091,0.00123916,0.0009210509],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004657981,"about_ca_system_score_gemma":0.0005257229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00103133,"about_ca_topic_score_gemma":0.003436544,"domain_scores_codex":[0.9996867,0.00007315174,0.00002741148,0.00003411697,0.0001060756,0.00007259853],"domain_scores_gemma":[0.9998643,0.00003135483,0.00002415459,0.00002989406,0.00001772699,0.00003242896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003105567,0.001652648,0.001778958,0.0004581717,0.0001638877,0.0004472996,0.000126681,0.001746329,0.9250078,0.0005130648,0.004140048,0.06085971],"study_design_scores_gemma":[0.0005749463,0.009193888,0.02395681,0.0000325587,0.0001674019,0.001561226,0.0001516524,0.003582211,0.9369367,0.0002734379,0.02353451,0.00003460545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810562,0.005144343,0.001569833,0.0005898426,0.0002650453,0.0001396165,0.001173616,0.0004858258,0.009575675],"genre_scores_gemma":[0.9872859,0.003901149,0.001406003,0.0001384843,0.000057918,0.0000809189,0.001872428,0.0000417042,0.005215512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003237163,"threshold_uncertainty_score":0.01082939,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2073369621","doi":"10.1007/s10637-005-5862-9","title":"A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Adverse effect; Rash; Cancer; Oncology; Nausea; Tolerability; Chemotherapy; Gastroenterology","authors":[{"name":"Mary J. MacKenzie","is_ca":true},{"name":"Holger W. Hirte","is_ca":true},{"name":"Glenwood D. Goss","is_ca":true},{"name":"Maroun Jean","is_ca":true},{"name":"Rakesh Goel","is_ca":true},{"name":"Pierre Major","is_ca":true},{"name":"Wilson H. Miller","is_ca":true},{"name":"Lawrence Panasci","is_ca":true},{"name":"Ian A.J. Lorimer","is_ca":true},{"name":"Gerald Batist","is_ca":true},{"name":"S. Matthews","is_ca":false},{"name":"L. Douglas","is_ca":true},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02695445011454185,"gpt":0.3051791641472074,"spread":0.2782247140326655,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009606758,0.001389126,0.002226341,0.0005156381,0.000430397,0.00071928,0.0006501324,0.0009898527,0.003649394],"category_scores_gemma":[0.0008611103,0.0005000234,0.001000411,0.0004986146,0.0009085152,0.0007937296,0.0002519464,0.002998662,0.0008066061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008193612,"about_ca_system_score_gemma":0.001269774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001701324,"about_ca_topic_score_gemma":0.005075675,"domain_scores_codex":[0.9997889,0.00009135393,0.00001034012,0.00003497463,0.00001914108,0.00005518962],"domain_scores_gemma":[0.9995102,0.00009343346,0.00005913746,0.0000292455,0.00002317805,0.0002848594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8685768,0.02058028,0.004041714,0.0006826501,0.0009908834,0.0002754401,0.0001897808,0.001939996,0.02064134,0.0003728233,0.005736889,0.07597134],"study_design_scores_gemma":[0.8286327,0.1585365,0.007381239,0.00002309086,0.0003479921,0.0002177622,0.00005036303,0.0007811504,0.001287359,0.000176504,0.002541962,0.00002348616],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890661,0.003594927,0.0005000499,0.001205943,0.0003945815,0.001343878,0.001345498,0.0001128198,0.002436002],"genre_scores_gemma":[0.9835707,0.004234549,0.001581452,0.001232833,0.0003383432,0.001032155,0.003187013,0.00003006886,0.004792904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003649394,"threshold_uncertainty_score":0.0122084,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2061189534","doi":"10.1007/s10637-009-9236-6","title":"Cyclin-dependent kinase inhibitors as potential targeted anticancer agents","year":2009,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyclin-dependent kinase; Kinase; Cell cycle; Cyclin; CDK inhibitor; Biology; Cancer research; Drug development; Cell biology; Cell; Drug; Pharmacology; Biochemistry","authors":[{"name":"Iván Díaz-Padilla","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Ignacio Durán","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03175408200627041,"gpt":0.324456682093521,"spread":0.2927026000872506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004586164,0.001000489,0.001309404,0.001530637,0.0002000495,0.0006722574,0.0007513544,0.0006065941,0.003516344],"category_scores_gemma":[0.0003985615,0.0003006737,0.0003353533,0.001532203,0.0004046026,0.001034095,0.0004682843,0.00150182,0.001832182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006019687,"about_ca_system_score_gemma":0.000629427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006228924,"about_ca_topic_score_gemma":0.002231332,"domain_scores_codex":[0.9998989,0.00001511116,0.00001407055,0.0000203938,0.00003690133,0.00001450836],"domain_scores_gemma":[0.9998797,0.00004911838,0.00002348023,0.000005330166,0.00002913814,0.00001322181],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001924703,0.0001491903,0.0001341519,0.006544248,0.00007641844,0.0002917547,0.00003511782,0.0006426648,0.006288972,0.003267657,0.02856404,0.9538134],"study_design_scores_gemma":[0.00007630078,0.0001744814,0.000569889,0.0008308673,0.0001643371,0.001147303,0.00002373432,0.0002377131,0.00244991,0.001136133,0.9931741,0.00001534995],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005542269,0.9945191,0.0005596572,0.0003111286,0.0003443561,0.00001990347,0.00004964172,0.00002405254,0.003617971],"genre_scores_gemma":[0.002510615,0.9940216,0.0006108359,0.000282245,0.0001783159,0.00001851507,0.00008424259,0.000003272826,0.002290285],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003516344,"threshold_uncertainty_score":0.01176333,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W235826207","doi":"10.1007/s10637-015-0252-4","title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Oncology; Circulating tumor cell; Clinical trial; Cancer; Surgery; Metastasis","authors":[{"name":"Bernhard J. Eigl","is_ca":true},{"name":"Scott North","is_ca":false},{"name":"Eric Winquist","is_ca":true},{"name":"Daygen L. Finch","is_ca":true},{"name":"Lori Wood","is_ca":true},{"name":"Srikala S. Sridhar","is_ca":true},{"name":"Jean Powers","is_ca":false},{"name":"Jennifer Good","is_ca":true},{"name":"Mansi Sharma","is_ca":false},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Jenny Bazov","is_ca":false},{"name":"Tamara Jamaspishvili","is_ca":true},{"name":"Michael Cox","is_ca":false},{"name":"Penelope A. Bradbury","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false},{"name":"K. N.","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08111566582937407,"gpt":0.401434337902309,"spread":0.320318672072935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001579114,0.002151772,0.002405399,0.0008105827,0.0006653154,0.001170885,0.001433115,0.00148632,0.006395847],"category_scores_gemma":[0.0008740762,0.0006831647,0.002451092,0.000773909,0.001077689,0.0008292502,0.0004529057,0.004352221,0.001435344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001282383,"about_ca_system_score_gemma":0.002226653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005059917,"about_ca_topic_score_gemma":0.01627305,"domain_scores_codex":[0.9995613,0.000219581,0.00001625628,0.00005851176,0.00003744152,0.0001070652],"domain_scores_gemma":[0.9992118,0.0001131398,0.0001038971,0.00006350321,0.00003222206,0.0004754418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7299582,0.07592463,0.008237666,0.001168645,0.002961408,0.0004314064,0.0004568969,0.004674492,0.04412534,0.0006135899,0.00973115,0.1217167],"study_design_scores_gemma":[0.6153644,0.3593542,0.01561974,0.00004820474,0.0008579642,0.0002779184,0.0001402529,0.001124249,0.002800685,0.0002252578,0.004133662,0.00005340843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807869,0.004727996,0.0009675038,0.001383438,0.0003233553,0.003216951,0.003882342,0.000257026,0.004454643],"genre_scores_gemma":[0.9766883,0.004479125,0.002141405,0.001704057,0.0002805755,0.002176249,0.006748036,0.00008611133,0.005696178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006395847,"threshold_uncertainty_score":0.02139622,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","authors":[{"name":"Andrew J. Armstrong","is_ca":false},{"name":"Ravit Geva","is_ca":false},{"name":"Hyun Cheol Chung","is_ca":false},{"name":"Charlotte Lemech","is_ca":false},{"name":"Wilson H. Miller","is_ca":true},{"name":"Aaron R. Hansen","is_ca":true},{"name":"Jong Seok Lee","is_ca":false},{"name":"Frank Tsai","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Tae Min Kim","is_ca":false},{"name":"Christian Rolfo","is_ca":false},{"name":"Vincent L. Giranda","is_ca":false},{"name":"Yixin Ren","is_ca":false},{"name":"Fang Liu","is_ca":false},{"name":"Bhargava Kandala","is_ca":false},{"name":"Tomoko Freshwater","is_ca":false},{"name":"Judy S. Wang","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01262812956067111,"gpt":0.3092178169209199,"spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001515112,0.001496121,0.001845241,0.0004011761,0.000374035,0.0009048561,0.0007395254,0.001276039,0.004554959],"category_scores_gemma":[0.0008833606,0.0005541429,0.001104232,0.0003784125,0.0007834567,0.0007979247,0.0002852644,0.002161647,0.0007676416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008044285,"about_ca_system_score_gemma":0.001141983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008916541,"about_ca_topic_score_gemma":0.002466495,"domain_scores_codex":[0.9996203,0.0002058475,0.00001801231,0.00005846156,0.00003082024,0.00006650363],"domain_scores_gemma":[0.9996044,0.00007954732,0.00009471737,0.00002999513,0.00002764952,0.000163649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9299379,0.01582317,0.001353342,0.000713977,0.0009353202,0.0001267051,0.0001146659,0.0009648429,0.008732216,0.0003195885,0.002862688,0.03811559],"study_design_scores_gemma":[0.9208757,0.07466237,0.00161378,0.00003165621,0.0002197044,0.00007229923,0.0000187959,0.0007665445,0.0004959474,0.000147006,0.00108544,0.00001088162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869722,0.003690443,0.0006683516,0.0008827922,0.0002763286,0.003914555,0.001054473,0.0001494874,0.002391362],"genre_scores_gemma":[0.981047,0.003483703,0.002121547,0.001462278,0.0004313927,0.006130613,0.001725716,0.00003028941,0.003567461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004554959,"threshold_uncertainty_score":0.01523787,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2073021016","doi":"10.1007/s10637-005-0793-z","title":"Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Renal cell carcinoma; Medicine; Carcinoma; Internal medicine; Oncology; Phases of clinical research; Chemotherapy","authors":[{"name":"Philip Shaheen","is_ca":false},{"name":"Walter M. Stadler","is_ca":false},{"name":"Paul Elson","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Eric Winquist","is_ca":true},{"name":"Ronald M. Bukowski","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01972554583441963,"gpt":0.2647082686783908,"spread":0.2449827228439712,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008105429,0.001002848,0.002730547,0.0003533187,0.0004107949,0.0007346649,0.0008075501,0.000883335,0.002507199],"category_scores_gemma":[0.0007149241,0.0004462014,0.0008783035,0.0004103741,0.001229098,0.0005452852,0.0002930877,0.003401972,0.0005483681],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001097281,"about_ca_system_score_gemma":0.001927803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002764986,"about_ca_topic_score_gemma":0.004830645,"domain_scores_codex":[0.9996674,0.0001748589,0.0000116322,0.00004824164,0.00002633678,0.00007147427],"domain_scores_gemma":[0.9995201,0.0001066821,0.00006455367,0.00004453772,0.00002269347,0.0002414633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7448692,0.08123733,0.007530922,0.0007193646,0.001356062,0.000510531,0.0003040951,0.003132218,0.05979674,0.0004692719,0.004151102,0.09592322],"study_design_scores_gemma":[0.5466919,0.4330442,0.009839546,0.00002202333,0.0004412385,0.0002883886,0.0000863653,0.001474531,0.005676793,0.0001906416,0.002211291,0.00003322076],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956329,0.001087751,0.0003547583,0.0003076402,0.00009133878,0.0009123337,0.0004413825,0.00005548823,0.001116245],"genre_scores_gemma":[0.9941426,0.00110075,0.0007545383,0.0004221132,0.0001042057,0.0007997588,0.0008549655,0.00002192037,0.001799232],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002764986,"threshold_uncertainty_score":0.008387446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015941325","doi":"10.1007/s10637-010-9494-3","title":"Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Oxaliplatin; Cisplatin; Cytoplasm; Liposome; Chemistry; DNA; Cancer cell; Intracellular; Cytotoxicity; Cancer research; Pharmacology; Molecular biology; Biochemistry; Biology; Colorectal cancer; Cancer; Chemotherapy; In vitro","authors":[{"name":"Thititip Tippayamontri","is_ca":true},{"name":"Rami Kotb","is_ca":true},{"name":"Benoît Paquette","is_ca":true},{"name":"Léon Sanche","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02019884188833627,"gpt":0.2418739762223202,"spread":0.221675134333984,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000164443,0.0001590004,0.0001973204,0.0001570386,0.0001602658,0.0002253364,0.0001389267,0.0002342908,0.001048836],"category_scores_gemma":[0.0001334423,0.0001383964,0.000125856,0.0002498433,0.0002079967,0.0002461575,0.00008054025,0.0002977903,0.0002243424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003243845,"about_ca_system_score_gemma":0.0002326107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004335374,"about_ca_topic_score_gemma":0.002904686,"domain_scores_codex":[0.9998907,0.00002446302,0.00001169798,0.00002798757,0.00002389317,0.00002133182],"domain_scores_gemma":[0.9999162,0.00002794596,0.00001482576,0.000008060994,0.00002258376,0.00001046257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003883153,0.00003058328,0.0003008759,0.00007852635,0.000006627984,0.00005282901,0.00004957486,0.0001418572,0.9974215,0.0001055702,0.00003751655,0.001386133],"study_design_scores_gemma":[0.00002467957,0.0005966144,0.005719581,0.000004816073,0.00002821104,0.0001348996,0.00006289206,0.001288149,0.9908589,0.00001977809,0.00125584,0.00000569154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942775,0.002150143,0.001252997,0.00008042748,0.00003016856,0.00001573862,0.0003018815,0.00002793677,0.001863174],"genre_scores_gemma":[0.9944495,0.0007848012,0.0009577102,0.00002732407,0.000007027087,0.00001678227,0.0002942219,0.00001006753,0.003452593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004335374,"threshold_uncertainty_score":0.008620262,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2072016597","doi":"10.1007/s10637-011-9700-y","title":"Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Apoptosis; Jurkat cells; Cell culture; Cell growth; Chemistry; Growth inhibition; Cell biology; Kinase; Flow cytometry; Cancer research; Molecular biology; Biology; Biochemistry; Immunology; T cell; Genetics","authors":[{"name":"Darya Habibi","is_ca":true},{"name":"Nadya Ogloff","is_ca":true},{"name":"Reza B. Jalili","is_ca":true},{"name":"Arla Yost","is_ca":true},{"name":"Andrew P. Weng","is_ca":true},{"name":"Aziz Ghahary","is_ca":true},{"name":"Christopher J. Ong","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02351559366078806,"gpt":0.2322449968493194,"spread":0.2087294031885313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001995184,0.0002184378,0.0003312919,0.0001760673,0.0001254991,0.0001673225,0.0001619139,0.0001552043,0.0004793914],"category_scores_gemma":[0.0001020396,0.0001088774,0.000123268,0.0001267073,0.0001318701,0.00009238174,0.0001264869,0.0003451848,0.0001902226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002083067,"about_ca_system_score_gemma":0.0001324751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002199421,"about_ca_topic_score_gemma":0.0007055387,"domain_scores_codex":[0.9999162,0.00002636797,0.000007662188,0.00001061499,0.00002043252,0.000018796],"domain_scores_gemma":[0.9999467,0.00001316479,0.00001561266,0.000005725807,0.000005330665,0.00001344269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00151446,0.0001053161,0.000577275,0.000132037,0.00001674568,0.0002524341,0.00001870867,0.0002660374,0.9679537,0.000261055,0.0003437353,0.02855852],"study_design_scores_gemma":[0.0004002532,0.004207215,0.004929841,0.000009323438,0.00004654593,0.00156973,0.00001353799,0.0006153149,0.9765371,0.000057011,0.01160505,0.000009077181],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746824,0.01880363,0.002472115,0.0002267579,0.00008518941,0.00005463062,0.0002011291,0.000148555,0.003325603],"genre_scores_gemma":[0.9889338,0.007009557,0.001868873,0.00008191638,0.00004030633,0.00003289663,0.0003361742,0.00001129111,0.00168526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0004793914,"threshold_uncertainty_score":0.001603782,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2013709636","doi":"10.1007/s10637-013-0001-5","title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Internal medicine; Pharmacokinetics; Pharmacology; Neutropenia; Rash; Gastroenterology; Oncology; Toxicity","authors":[{"name":"Iván Díaz-Padilla","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Blaise Clarke","is_ca":true},{"name":"Brenda Cohen","is_ca":true},{"name":"Michael Reedjik","is_ca":true},{"name":"Tong Zhang","is_ca":true},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"S. Percy Ivy","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Albiruni Abdul Razak","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Irene Braña","is_ca":true},{"name":"Monika Wizemann","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01450826635240509,"gpt":0.2992024669756905,"spread":0.2846942006232854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00133471,0.001267602,0.002212542,0.0004633852,0.0004162599,0.0008190469,0.0008531745,0.0009827056,0.002910263],"category_scores_gemma":[0.0006605507,0.0006071945,0.001158866,0.0004955518,0.0008667017,0.0007170069,0.0003879124,0.002911738,0.001030194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026822,"about_ca_system_score_gemma":0.002013037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007549436,"about_ca_topic_score_gemma":0.001789196,"domain_scores_codex":[0.9994664,0.000230728,0.00004246419,0.00009426187,0.00006684269,0.00009940763],"domain_scores_gemma":[0.999313,0.00008724877,0.000121524,0.00006996409,0.00004226807,0.0003659733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5706529,0.1212778,0.01776156,0.0009933236,0.002279641,0.00069099,0.0005196876,0.005312847,0.1447667,0.0003538865,0.004875249,0.1305155],"study_design_scores_gemma":[0.3764508,0.5950996,0.01522719,0.00003163366,0.0004688692,0.0005651303,0.00007970179,0.001569505,0.007041256,0.0001423029,0.003290317,0.0000337218],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939098,0.001401469,0.0005140537,0.0003358618,0.00008434196,0.001917394,0.0005242583,0.00006530675,0.001247551],"genre_scores_gemma":[0.9921368,0.0009912978,0.001694233,0.0005997861,0.0001158329,0.001802347,0.001449094,0.0000218082,0.001188878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002910263,"threshold_uncertainty_score":0.009735763,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2795799317","doi":"10.1007/s10637-018-0591-z","title":"A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Pharmacodynamics; Adverse effect; Internal medicine; Gastroenterology; Nausea; Pharmacology","authors":[{"name":"Carol Aghajanian","is_ca":false},{"name":"Katherine M. Bell‐McGuinn","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Lee-Ann Stayner","is_ca":true},{"name":"Jennifer J. Wheler","is_ca":false},{"name":"David S. Hong","is_ca":false},{"name":"Carla Kurkjian","is_ca":false},{"name":"Shubham Pant","is_ca":false},{"name":"Ademi Santiago-Walker","is_ca":false},{"name":"Jennifer Gauvin","is_ca":false},{"name":"Joyce Antal","is_ca":false},{"name":"Joanna Opalinska","is_ca":false},{"name":"Shannon R. Morris","is_ca":false},{"name":"Jeffrey R. Infante","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02342681837866611,"gpt":0.3401203968094243,"spread":0.3166935784307582,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002090713,0.002266954,0.0035368,0.0006471836,0.0006748999,0.001176839,0.001042072,0.001605001,0.00416798],"category_scores_gemma":[0.001238108,0.001004276,0.002018026,0.0006583645,0.001853989,0.002036371,0.0005124108,0.004752393,0.00105428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001380291,"about_ca_system_score_gemma":0.002826961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001053469,"about_ca_topic_score_gemma":0.002795039,"domain_scores_codex":[0.999353,0.0002416591,0.00002978372,0.0001419319,0.00006140544,0.0001722648],"domain_scores_gemma":[0.9989049,0.0001705579,0.0001697137,0.0001455933,0.00005847774,0.0005507511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7612383,0.1273113,0.005931518,0.0006123325,0.001053848,0.0002649998,0.0003162112,0.002714981,0.03278452,0.0003777208,0.002729193,0.06466518],"study_design_scores_gemma":[0.4471851,0.540849,0.006112595,0.00001355343,0.0003055442,0.0001736609,0.00006357412,0.0009678251,0.002583477,0.0002262074,0.001482961,0.00003645299],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901214,0.001342236,0.001038971,0.0004362645,0.0001855023,0.004045502,0.001246416,0.0001090048,0.001474852],"genre_scores_gemma":[0.9805418,0.001683742,0.00325552,0.001172207,0.0002931354,0.006153495,0.002701756,0.00006679785,0.004131435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00416798,"threshold_uncertainty_score":0.01394325,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2050197847","doi":"10.1007/s10637-014-0159-5","title":"A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Doxorubicin; Pharmacokinetics; Pantoprazole; Medicine; Pharmacology; Chemotherapy; Internal medicine","authors":[{"name":"Irene Braña","is_ca":true},{"name":"Alberto Ocaña","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Christine Haines","is_ca":true},{"name":"Carol Lee","is_ca":true},{"name":"Sarah F. Douglas","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Ian F. Tannock","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01229624724605933,"gpt":0.2958925228316514,"spread":0.283596275585592,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001166142,0.002066482,0.003308749,0.0006988036,0.0005983904,0.001202869,0.001198672,0.002050477,0.003134801],"category_scores_gemma":[0.001271082,0.0009026509,0.001738866,0.0009666457,0.001653982,0.001495375,0.0004704944,0.004744567,0.0009014884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001484303,"about_ca_system_score_gemma":0.00204629,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002058123,"about_ca_topic_score_gemma":0.00558375,"domain_scores_codex":[0.9994231,0.0002529875,0.0000233905,0.0001141612,0.0000429753,0.0001433417],"domain_scores_gemma":[0.9989809,0.0002091268,0.0001444722,0.0000942773,0.00005440057,0.000516711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8280819,0.04330454,0.004879894,0.0006530506,0.001350766,0.0003598901,0.0004199136,0.003580057,0.03816657,0.0004123354,0.003139229,0.07565183],"study_design_scores_gemma":[0.5637164,0.4217127,0.007366919,0.00002404579,0.0004672202,0.0002614856,0.00009459901,0.001332752,0.00327228,0.0001287023,0.001583903,0.00003911837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938787,0.001670588,0.00048333,0.000731857,0.0001605691,0.001055341,0.0006724395,0.00009100019,0.001256281],"genre_scores_gemma":[0.9905332,0.00219612,0.001423149,0.000597091,0.000202672,0.001360502,0.001585313,0.00005229289,0.002049667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003308749,"threshold_uncertainty_score":0.01076943,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000023204","doi":"10.1007/s10637-010-9570-8","title":"A phase I study of temsirolimus and metformin in advanced solid tumours","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Temsirolimus; Metformin; Medicine; Internal medicine; Maximum tolerated dose; Toxicity; Cancer; Limiting; Gastroenterology; Discovery and development of mTOR inhibitors","authors":[{"name":"Mary J. MacKenzie","is_ca":true},{"name":"Scott Ernst","is_ca":true},{"name":"Craig A. Johnson","is_ca":true},{"name":"Eric Winquist","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01204302114974114,"gpt":0.3080307372402999,"spread":0.2959877160905588,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001767688,0.00139358,0.003019271,0.0008107511,0.0006202308,0.00112226,0.001157447,0.001592134,0.003158692],"category_scores_gemma":[0.0006609345,0.0007967436,0.001884383,0.000746936,0.00116067,0.001210522,0.0004340331,0.003547461,0.00067883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068117,"about_ca_system_score_gemma":0.002152994,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001575287,"about_ca_topic_score_gemma":0.004290077,"domain_scores_codex":[0.9995022,0.0002132948,0.00002378444,0.00008626029,0.00004888845,0.0001256111],"domain_scores_gemma":[0.9994125,0.00008805504,0.0000787063,0.00006723086,0.00003244443,0.0003210716],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6860719,0.09546334,0.004728021,0.001106031,0.002499153,0.0003799312,0.0003823353,0.005567672,0.09469169,0.001009847,0.00521369,0.1028864],"study_design_scores_gemma":[0.4805309,0.4977256,0.005867115,0.00003326899,0.0007449933,0.0003103041,0.00009531022,0.001095502,0.008716499,0.0002802798,0.004548431,0.00005174421],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904417,0.003557904,0.0006423311,0.0006446269,0.0002534548,0.001766894,0.0009600356,0.00007284367,0.001660316],"genre_scores_gemma":[0.9823278,0.004545188,0.002631207,0.0009162131,0.0002553603,0.002783828,0.002497114,0.00005975497,0.003983505],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003158692,"threshold_uncertainty_score":0.01056689,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089379119","doi":"10.1007/s10637-010-9626-9","title":"Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"RAD51; Molecular biology; DNA-PKcs; DNA damage; Irinotecan; Comet assay; Cancer research; DNA repair; DNA; Chemistry; Homologous recombination; DNA ligase; Biology; Colorectal cancer; Cancer; Biochemistry; Genetics","authors":[{"name":"David Davidson","is_ca":true},{"name":"Yannick Coulombe","is_ca":true},{"name":"Verónica L. Martínez‐Marignac","is_ca":true},{"name":"Lilian Amrein","is_ca":true},{"name":"Jeremy Grenier","is_ca":true},{"name":"Keira Hodkinson","is_ca":true},{"name":"Jean‐Yves Masson","is_ca":true},{"name":"Raquel Aloyz","is_ca":true},{"name":"Lawrence Panasci","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0160094944983551,"gpt":0.2261960770657665,"spread":0.2101865825674114,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003034741,0.0004713992,0.0006438546,0.0007931057,0.0002758555,0.0003886868,0.0002726515,0.0003006639,0.002268994],"category_scores_gemma":[0.0002484846,0.0002659005,0.0003320571,0.0006065738,0.0002679274,0.0003425807,0.0002582429,0.000663555,0.0004191276],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005530158,"about_ca_system_score_gemma":0.0006080707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001080741,"about_ca_topic_score_gemma":0.004312851,"domain_scores_codex":[0.9996996,0.00008040397,0.00002100858,0.00002364353,0.00008732798,0.00008800887],"domain_scores_gemma":[0.9998534,0.00004643908,0.00002463063,0.00002417975,0.00001310129,0.00003825797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00449536,0.0004994977,0.0009276703,0.0002470087,0.00007868896,0.0003078454,0.00006591327,0.001013068,0.9593537,0.0004801548,0.0007438273,0.03178725],"study_design_scores_gemma":[0.0003687831,0.005173629,0.01186713,0.00001701935,0.0001036973,0.0009761893,0.00007584389,0.001212216,0.9695007,0.0001527131,0.01053538,0.00001666656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769299,0.01332853,0.0007651278,0.0003926206,0.0001421641,0.00008457686,0.0003845136,0.0001561022,0.007816429],"genre_scores_gemma":[0.9871574,0.005914505,0.0008293894,0.00007089561,0.00005566178,0.00004063094,0.0003741631,0.00001378467,0.005543579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002268994,"threshold_uncertainty_score":0.007590532,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2337001617","doi":"10.1007/s10637-016-0351-x","title":"A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Irinotecan; Medicine; Tolerability; Internal medicine; Regimen; Oncology; Neutropenia; PARP inhibitor; Colorectal cancer; Cancer; Chemotherapy; Adverse effect","authors":[{"name":"Eric X. Chen","is_ca":true},{"name":"Derek J. Jonker","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Karyn McKeever","is_ca":true},{"name":"Deborah S. Keller","is_ca":false},{"name":"Julie Wells","is_ca":false},{"name":"Linda Hagerman","is_ca":false},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03639334982599422,"gpt":0.3302634596488522,"spread":0.293870109822858,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001971608,0.001542357,0.002488875,0.0005447629,0.00103275,0.001195682,0.001211797,0.001481524,0.005540517],"category_scores_gemma":[0.00129145,0.0006816042,0.002291899,0.00119932,0.001365002,0.0005792364,0.0004476326,0.004102436,0.0008246754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004946951,"about_ca_system_score_gemma":0.01403036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1016788,"about_ca_topic_score_gemma":0.3116298,"domain_scores_codex":[0.9992504,0.0003082754,0.00002295351,0.0000952862,0.0001034013,0.0002196453],"domain_scores_gemma":[0.9988944,0.0001460895,0.0001260523,0.00006740504,0.0001128896,0.0006531442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8122028,0.02705969,0.008759258,0.001401943,0.002491116,0.0003345277,0.0004268036,0.002658627,0.01155695,0.0006437868,0.02338249,0.1090819],"study_design_scores_gemma":[0.8212768,0.1376027,0.02451063,0.00008378327,0.001227421,0.0002421195,0.0001363818,0.0007854371,0.0009992409,0.0002358154,0.01283458,0.00006511639],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9502436,0.0147176,0.0007026285,0.004657306,0.0005050848,0.007433338,0.01064435,0.0001691004,0.010927],"genre_scores_gemma":[0.9418556,0.01657299,0.00457874,0.005025383,0.000467078,0.005149713,0.0129885,0.0001082532,0.01325378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1016788,"threshold_uncertainty_score":0.2021738,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2033997665","doi":"10.1007/s10637-011-9650-4","title":"A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Cancer; Gastroenterology; Clinical endpoint; Adenocarcinoma; Oncology; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","authors":[{"name":"Helen Mackay","is_ca":true},{"name":"H. Au","is_ca":true},{"name":"Elaine McWhirter","is_ca":true},{"name":"Thierry Alcindor","is_ca":true},{"name":"A. Järvi","is_ca":true},{"name":"K. MacAlpine","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Amit M. Oza","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03554854809381155,"gpt":0.2814283974656747,"spread":0.2458798493718632,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001648198,0.001634575,0.001830382,0.0003569131,0.0003755741,0.0009199936,0.0007783018,0.00128732,0.004496283],"category_scores_gemma":[0.001208109,0.0004456613,0.001385772,0.0003321898,0.0009300949,0.000969063,0.000469706,0.004198169,0.0008341189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000827162,"about_ca_system_score_gemma":0.001216917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009488038,"about_ca_topic_score_gemma":0.003292269,"domain_scores_codex":[0.9996514,0.0001889241,0.00001143225,0.00005828268,0.0000254006,0.00006458082],"domain_scores_gemma":[0.9993939,0.0001217841,0.00008500953,0.00004452301,0.00002686771,0.0003277564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7773586,0.03053221,0.007993081,0.001070854,0.002020115,0.0003337041,0.0002666052,0.004199497,0.01835596,0.0009880101,0.0190521,0.1378293],"study_design_scores_gemma":[0.8897921,0.09707935,0.006806516,0.00002704796,0.0003856882,0.0002145236,0.00005348727,0.00142752,0.001087763,0.0004604335,0.002642678,0.00002280838],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859757,0.003360706,0.0004865148,0.002975326,0.0004525489,0.001618997,0.002048064,0.0001068464,0.002975353],"genre_scores_gemma":[0.9791712,0.003298122,0.002272837,0.002927098,0.0004888526,0.001984236,0.004822943,0.00004228228,0.004992405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004496283,"threshold_uncertainty_score":0.01504153,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047528221","doi":"10.1007/s10637-010-9611-3","title":"A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Essar Steel Algoma (Canada); BC Cancer Agency; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Clinical endpoint; Oncology; Progressive disease; Phases of clinical research; Stage (stratigraphy); Deoxycytidine; Cancer; Chemotherapy; Clinical trial; Gastroenterology","authors":[{"name":"Daniel J. Renouf","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true},{"name":"David W. Hedley","is_ca":true},{"name":"Sharlene Gill","is_ca":true},{"name":"Derek J. Jonker","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"David Walde","is_ca":true},{"name":"Rakesh Goel","is_ca":true},{"name":"Bernadette Southwood","is_ca":true},{"name":"Isabelle Gauthier","is_ca":false},{"name":"Wendy Walsh","is_ca":false},{"name":"L. McIntosh","is_ca":false},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02456104693955328,"gpt":0.3483358976497588,"spread":0.3237748507102055,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001598104,0.001637259,0.002858205,0.0007894281,0.0005484599,0.001322284,0.0009625683,0.001366951,0.003266637],"category_scores_gemma":[0.0007803772,0.000907433,0.001899939,0.0007328881,0.001444102,0.001400915,0.0004315455,0.004258696,0.0009305577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001092283,"about_ca_system_score_gemma":0.001799132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001479538,"about_ca_topic_score_gemma":0.004960762,"domain_scores_codex":[0.9995769,0.000192121,0.00002247678,0.00007110728,0.00003636976,0.0001010287],"domain_scores_gemma":[0.999433,0.00009090701,0.00007666667,0.00005839945,0.00002858174,0.0003125127],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6804173,0.1291572,0.005633905,0.001274803,0.002129514,0.0005293061,0.0004187388,0.005531215,0.0513105,0.0006206513,0.006053152,0.1169237],"study_design_scores_gemma":[0.543148,0.4389701,0.007720801,0.000037643,0.0006627146,0.0003504401,0.0001103607,0.001612229,0.003995608,0.0002532857,0.003094486,0.00004438361],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908059,0.003005553,0.000510981,0.0007249038,0.0002316134,0.001860602,0.0009398477,0.0001021973,0.001818382],"genre_scores_gemma":[0.9849336,0.005020354,0.001912964,0.0008830995,0.0002280154,0.001778094,0.002211838,0.00004609449,0.002985958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003266637,"threshold_uncertainty_score":0.01092798,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2597378792","doi":"10.1007/s10637-017-0450-3","title":"A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Quebec Rehabilitation Research Network","funders":"University of Minnesota","keywords":"Carboplatin; Cetuximab; Medicine; Clinical endpoint; Paclitaxel; Internal medicine; Oncology; Adverse effect; Phases of clinical research; Chemotherapy; Lung cancer; Randomized controlled trial; Cancer; Colorectal cancer; Cisplatin","authors":[{"name":"Michael Thomas","is_ca":false},{"name":"Parvis Sadjadian","is_ca":false},{"name":"Jens Kollmeier","is_ca":false},{"name":"Jamie Lowe","is_ca":false},{"name":"Paulette Mattson","is_ca":false},{"name":"J. Richard Trout","is_ca":false},{"name":"Michele Gargano","is_ca":false},{"name":"Myra L. Patchen","is_ca":false},{"name":"Richard M. Walsh","is_ca":false},{"name":"Martin Béliveau","is_ca":true},{"name":"Jean‐Francois Marier","is_ca":true},{"name":"Nandita Bose","is_ca":false},{"name":"Keith Gorden","is_ca":false},{"name":"Folker Schneller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02367520973491477,"gpt":0.344474568354692,"spread":0.3207993586197773,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239037,0.001835076,0.002706117,0.00036881,0.0004349716,0.0008974937,0.0008468174,0.001236619,0.004795606],"category_scores_gemma":[0.001345177,0.0008895662,0.001053207,0.0003537926,0.001584746,0.0009275064,0.0004067789,0.003034534,0.001124441],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009780732,"about_ca_system_score_gemma":0.002738784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007904224,"about_ca_topic_score_gemma":0.00218837,"domain_scores_codex":[0.9992048,0.0004663854,0.00003515133,0.0001229127,0.00005752304,0.0001131969],"domain_scores_gemma":[0.998646,0.0002579638,0.0002664546,0.0001201646,0.00008651613,0.0006229482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9376539,0.03509626,0.001117301,0.0002368262,0.0004657255,0.00006084415,0.0000719247,0.0004380067,0.009140722,0.0001336247,0.001103849,0.01448101],"study_design_scores_gemma":[0.8456641,0.1509739,0.001386581,0.000008403558,0.0001524291,0.00002975461,0.00001553265,0.0004256578,0.0007294418,0.00007576196,0.000528638,0.000009789326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892231,0.0009037828,0.0007187637,0.0003603547,0.0003130174,0.006345413,0.0007025524,0.00008565681,0.001347381],"genre_scores_gemma":[0.9816574,0.001085862,0.002575707,0.001107654,0.0005177264,0.008561039,0.001374554,0.00004023349,0.003079966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004795606,"threshold_uncertainty_score":0.01604289,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2056723407","doi":"10.1007/s10637-008-9143-2","title":"O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","year":2008,"lang":"fr","type":"article","venue":"Investigational New Drugs","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Mashhad University of Medical Sciences","keywords":"Medicine; Imatinib mesylate; Adverse effect; Phases of clinical research; Clinical trial; Melanoma; Internal medicine; Imatinib; Surgery; Oncology; Gastroenterology","authors":[{"name":"Nicolas Penel","is_ca":false},{"name":"Corinne Delcambre","is_ca":false},{"name":"Xavier Durando","is_ca":false},{"name":"Stéphanie Clisant","is_ca":false},{"name":"Mohamed Hebbar","is_ca":false},{"name":"Sylvie Négrier","is_ca":false},{"name":"Charles Fournier","is_ca":false},{"name":"Nicolás Isambert","is_ca":false},{"name":"Frédéric Mascarelli","is_ca":false},{"name":"F. Mouriaux","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04069337693991506,"gpt":0.3313887372190749,"spread":0.2906953602791599,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001532279,0.0009052611,0.001318477,0.0003910664,0.0004358615,0.001282362,0.0006215755,0.0009294535,0.002976081],"category_scores_gemma":[0.0007564995,0.000318116,0.0008689695,0.0003495442,0.0006724817,0.0007971259,0.0004015243,0.002342496,0.000530728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071376,"about_ca_system_score_gemma":0.001339871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002407223,"about_ca_topic_score_gemma":0.01140443,"domain_scores_codex":[0.9996898,0.0001385615,0.000009870158,0.00003783366,0.00002526392,0.00009863106],"domain_scores_gemma":[0.9994953,0.00007565739,0.00006217403,0.00002246196,0.00002229275,0.0003221155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6769642,0.03998912,0.01291285,0.001240448,0.001763452,0.0006550428,0.0004979821,0.005796002,0.05535464,0.001458772,0.02411406,0.1792535],"study_design_scores_gemma":[0.8065856,0.1439958,0.02507978,0.0001446607,0.0009699442,0.0007329703,0.0002649362,0.003135635,0.004469988,0.0008859457,0.01366666,0.0000680907],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987298,0.004791189,0.0002882956,0.001558469,0.0002696864,0.0006397364,0.001191553,0.00008219858,0.003880888],"genre_scores_gemma":[0.9814633,0.004392017,0.001785047,0.0013446,0.0002471138,0.0007911861,0.003418049,0.00004966021,0.006509081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002976081,"threshold_uncertainty_score":0.009956002,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166042057","doi":"10.1007/s10637-011-9660-2","title":"Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Myeloid leukemia; Refractory (planetary science); Pharmacology; Internal medicine; Adverse effect; Gastroenterology","authors":[{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Swaminathan P. Iyer","is_ca":false},{"name":"Wendy Stock","is_ca":false},{"name":"Martin S. Tallman","is_ca":false},{"name":"Gregory A. Curt","is_ca":false},{"name":"J. Li","is_ca":false},{"name":"Anna Osmukhina","is_ca":false},{"name":"Kang Wu","is_ca":false},{"name":"Dennis Huszar","is_ca":false},{"name":"G. Borthukar","is_ca":false},{"name":"Stefan Faderl","is_ca":false},{"name":"Guillermo Garcia‐Manero","is_ca":false},{"name":"Tapan M. Kadia","is_ca":false},{"name":"Kamalesh K. Sankhala","is_ca":false},{"name":"Olatoyosi Odenike","is_ca":false},{"name":"Jessica K. Altman","is_ca":false},{"name":"Mark D. Minden","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03847222243353014,"gpt":0.3291154967498259,"spread":0.2906432743162958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001567215,0.00147226,0.002773592,0.0004115565,0.0005025467,0.0007748573,0.0007761655,0.0009082992,0.002689227],"category_scores_gemma":[0.001033484,0.0004603509,0.0009516689,0.0004218119,0.00116154,0.0008439156,0.0003537868,0.002607574,0.0008124645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007416441,"about_ca_system_score_gemma":0.00131194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008959177,"about_ca_topic_score_gemma":0.001268524,"domain_scores_codex":[0.9994072,0.0003279061,0.00002352794,0.00007517011,0.00004350657,0.0001227748],"domain_scores_gemma":[0.9991635,0.0001364688,0.0001344534,0.00009379953,0.0000494642,0.0004223047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7855046,0.05633148,0.01814091,0.0004022801,0.001420059,0.000462223,0.0002706865,0.00267138,0.050254,0.000439653,0.004583422,0.0795192],"study_design_scores_gemma":[0.6196616,0.3507289,0.02100437,0.00001739086,0.000428771,0.0004078932,0.00006486884,0.001480644,0.003471676,0.0001842495,0.002517517,0.0000321528],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947556,0.001167437,0.0004887489,0.0003722591,0.00007783443,0.00132494,0.0007627844,0.00006093525,0.0009894338],"genre_scores_gemma":[0.9902575,0.001028972,0.001647277,0.0009149631,0.0002295268,0.00211329,0.002114278,0.00003611478,0.001658151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002773592,"threshold_uncertainty_score":0.008996308,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2020555572","doi":"10.1007/s10637-013-0055-4","title":"Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"U.S. Food and Drug Administration; GlaxoSmithKline","keywords":"Lapatinib; Pharmacokinetics; Cmax; Medicine; Meal; Tolerability; Pharmacology; Internal medicine; Gastroenterology; Adverse effect; Cancer; Breast cancer; Trastuzumab","authors":[{"name":"Lot A. Devriese","is_ca":false},{"name":"Kevin M. Koch","is_ca":false},{"name":"Marja Mergui‐Roelvink","is_ca":false},{"name":"Gemma M. Matthys","is_ca":false},{"name":"Wen Wee","is_ca":false},{"name":"André Robidoux","is_ca":true},{"name":"Joe Stephenson","is_ca":false},{"name":"Quincy S. Chu","is_ca":false},{"name":"Keith Orford","is_ca":false},{"name":"Leanne Cartee","is_ca":false},{"name":"Jeff Botbyl","is_ca":false},{"name":"Nikita Arya","is_ca":false},{"name":"Jan H.M. Schellens","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005263758791417631,"gpt":0.2631291230371833,"spread":0.2578653642457657,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005940526,0.0003943203,0.001119968,0.0001663129,0.0002348604,0.0005601539,0.0002093672,0.0004507285,0.001530534],"category_scores_gemma":[0.002019414,0.0002588397,0.0006918823,0.0002352966,0.0003605668,0.0008784311,0.0003010279,0.00158195,0.0002039617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005985535,"about_ca_system_score_gemma":0.0004863907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001504044,"about_ca_topic_score_gemma":0.002338554,"domain_scores_codex":[0.9996501,0.000166948,0.00002105343,0.00005071025,0.00003407942,0.00007702407],"domain_scores_gemma":[0.9993087,0.0003367922,0.0001033038,0.00005114815,0.00003565714,0.0001644106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7947322,0.004609817,0.04260669,0.0001917323,0.001665085,0.0003446326,0.0002718106,0.003329381,0.04779743,0.0001686076,0.001415838,0.1028669],"study_design_scores_gemma":[0.03792792,0.2651288,0.6281993,0.00007351681,0.003576283,0.001205077,0.0008968056,0.01670897,0.04021743,0.0006392035,0.005195513,0.000231264],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987804,0.0005663609,0.00007875079,0.00008500581,0.00002455238,0.00001262771,0.0000982393,0.0000178644,0.0003360996],"genre_scores_gemma":[0.9990482,0.0001945789,0.0001359036,0.00009142041,0.00002130188,0.0000152618,0.0001534325,0.00001051913,0.0003294151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001530534,"threshold_uncertainty_score":0.005120099,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2068833931","doi":"10.1007/s10637-008-9184-6","title":"Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Calcitriol; Medicine; Pancreatic cancer; Internal medicine; Oncology; Cancer; Cancer research; Calcium","authors":[{"name":"Charles D. Blanke","is_ca":true},{"name":"Tomasz M. Beer","is_ca":false},{"name":"Kendra Todd","is_ca":false},{"name":"Motomi Mori","is_ca":false},{"name":"Michelle K. Stone","is_ca":false},{"name":"Charles D. Lopez","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04046030513904524,"gpt":0.3491620148261989,"spread":0.3087017096871537,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00125925,0.001577297,0.003018116,0.0005828384,0.0006767419,0.001476042,0.001111154,0.001256234,0.003459282],"category_scores_gemma":[0.000907672,0.0008038251,0.001508047,0.0007073609,0.001594616,0.001004039,0.0003959798,0.004287837,0.0009371874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001451909,"about_ca_system_score_gemma":0.002473932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004259155,"about_ca_topic_score_gemma":0.009895863,"domain_scores_codex":[0.9995857,0.0001600801,0.00001535372,0.00008156356,0.00003085093,0.0001264921],"domain_scores_gemma":[0.9992737,0.0001311725,0.00009322286,0.00006589644,0.00003416101,0.0004018076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7230403,0.1198413,0.007950253,0.0008972535,0.001628959,0.0006086057,0.0007391652,0.005828693,0.03875491,0.0006060656,0.004508068,0.09559638],"study_design_scores_gemma":[0.490141,0.4937225,0.008158169,0.000031994,0.0005056339,0.0002743134,0.0001302791,0.001201811,0.00299897,0.0001702827,0.002629848,0.00003512052],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928738,0.001876004,0.0004744701,0.0004642758,0.0001802064,0.001678767,0.0007140452,0.00007099639,0.00166731],"genre_scores_gemma":[0.9904143,0.002369267,0.0009621883,0.0005086562,0.0001609957,0.001263526,0.001226977,0.00003732143,0.00305679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004259155,"threshold_uncertainty_score":0.01157242,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","authors":[{"name":"Glenwood Goss","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Wilson H. Miller","is_ca":true},{"name":"Ian Lorimer","is_ca":true},{"name":"David J. Stewart","is_ca":true},{"name":"Gerald Batist","is_ca":true},{"name":"D A E Parolin","is_ca":true},{"name":"Peter Hanna","is_ca":true},{"name":"S. Stafford","is_ca":true},{"name":"Jennifer Friedmann","is_ca":true},{"name":"William R. Walsh","is_ca":false},{"name":"Sara Mathews","is_ca":false},{"name":"L. Douglas","is_ca":true},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1409265698095374,"gpt":0.4577079910447914,"spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001707711,0.002906749,0.004372895,0.0008453325,0.0006848984,0.001309382,0.001148047,0.001742103,0.005540175],"category_scores_gemma":[0.001494217,0.00102398,0.002090459,0.0007576622,0.001340779,0.001072424,0.0003741528,0.004835879,0.001690491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009713415,"about_ca_system_score_gemma":0.002042409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002014685,"about_ca_topic_score_gemma":0.004770187,"domain_scores_codex":[0.9995348,0.0002394167,0.00001806156,0.00006392996,0.00004398676,0.00009976823],"domain_scores_gemma":[0.9989473,0.0002059916,0.0001433923,0.0000872969,0.00005932184,0.0005567085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8218663,0.06527223,0.003528353,0.0008869732,0.001198088,0.0002895299,0.0002526314,0.00241223,0.02556969,0.0003796311,0.009664354,0.06867995],"study_design_scores_gemma":[0.7700303,0.2202482,0.005238994,0.00001806939,0.0003190977,0.0001767757,0.00004369281,0.0008814906,0.001219169,0.0001266058,0.001662283,0.00003538436],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852186,0.002398046,0.0006780874,0.001116458,0.0002923056,0.002495764,0.003641396,0.0002765887,0.003882798],"genre_scores_gemma":[0.9722748,0.004432375,0.00255535,0.001651902,0.0004404846,0.002742914,0.007138533,0.000116897,0.008646777],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005540175,"threshold_uncertainty_score":0.01853371,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}